<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections - Schuetz, P - 2017 | Cochrane Library</title> <meta content="Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections - Schuetz, P - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007498.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections - Schuetz, P - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007498.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007498.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections" name="citation_title"/> <meta content="Philipp Schuetz" name="citation_author"/> <meta content="schuetzph@gmail.com" name="citation_author_email"/> <meta content="Yannick Wirz" name="citation_author"/> <meta content="Kantonsspital Aarau" name="citation_author_institution"/> <meta content="Ramon Sager" name="citation_author"/> <meta content="Kantonsspital Aarau" name="citation_author_institution"/> <meta content="Mirjam Christ‐Crain" name="citation_author"/> <meta content="University Hospital Basel, University of Basel" name="citation_author_institution"/> <meta content="Daiana Stolz" name="citation_author"/> <meta content="University Hospital Basel" name="citation_author_institution"/> <meta content="Michael Tamm" name="citation_author"/> <meta content="University Hospital Basel" name="citation_author_institution"/> <meta content="Lila Bouadma" name="citation_author"/> <meta content="Hôpital Bichat‐Claude Bernard, Université Paris 7‐Denis‐Diderot" name="citation_author_institution"/> <meta content="Charles E Luyt" name="citation_author"/> <meta content="Groupe Hospitalier Pitié‐Salpêtrière, Assistance Publique–Hôpitaux de Paris, Université Paris 6‐Pierre‐et‐Marie‐Curie" name="citation_author_institution"/> <meta content="Michel Wolff" name="citation_author"/> <meta content="Université Paris 7‐Denis‐Diderot" name="citation_author_institution"/> <meta content="Jean Chastre" name="citation_author"/> <meta content="Université Paris 6‐Pierre‐et‐Marie‐Curie" name="citation_author_institution"/> <meta content="Florence Tubach" name="citation_author"/> <meta content="Santé Publique et Information Médicale, AP‐HP, Groupe Hospitalier Pitié‐Salpêtrière Charles‐Foix, INSERM CIC‐P 1421, Sorbonne Universités, UPMC Univ Paris 06" name="citation_author_institution"/> <meta content="Kristina B Kristoffersen" name="citation_author"/> <meta content="Aarhus University Hospital" name="citation_author_institution"/> <meta content="Olaf Burkhardt" name="citation_author"/> <meta content="Medizinische Hochschule Hannover" name="citation_author_institution"/> <meta content="Tobias Welte" name="citation_author"/> <meta content="Stefan Schroeder" name="citation_author"/> <meta content="Krankenhaus Dueren" name="citation_author_institution"/> <meta content="Vandack Nobre" name="citation_author"/> <meta content="Universidade Federal de Minas Gerais" name="citation_author_institution"/> <meta content="Long Wei" name="citation_author"/> <meta content="Shanghai Jiao Tong University Affiliated Sixth People's Hospital (East campus)" name="citation_author_institution"/> <meta content="Heiner C C Bucher" name="citation_author"/> <meta content="Neera Bhatnagar" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Djillali Annane" name="citation_author"/> <meta content="Center for Neuromuscular Diseases" name="citation_author_institution"/> <meta content="Konrad Reinhart" name="citation_author"/> <meta content=" Raymond Poincaré Hospital (AP‐HP)" name="citation_author_institution"/> <meta content="Angela Branche" name="citation_author"/> <meta content="Jena University Hospital" name="citation_author_institution"/> <meta content="Pierre Damas" name="citation_author"/> <meta content="University of Rochester School of Medicine" name="citation_author_institution"/> <meta content="Maarten Nijsten" name="citation_author"/> <meta content="University Hospital of Liege, Domaine universitaire de Liège" name="citation_author_institution"/> <meta content="Dylan W de Lange" name="citation_author"/> <meta content="University of Groningen" name="citation_author_institution"/> <meta content="Rodrigo O Deliberato" name="citation_author"/> <meta content="University Medical Center Utrecht" name="citation_author_institution"/> <meta content="Stella SS Lima" name="citation_author"/> <meta content="Hospital Israelita Albert Einstein" name="citation_author_institution"/> <meta content="Vera Maravić‐Stojković" name="citation_author"/> <meta content="Universidade Federal de Minas Gerais" name="citation_author_institution"/> <meta content="Alessia Verduri" name="citation_author"/> <meta content="Dedinje Cardiovascular Institute" name="citation_author_institution"/> <meta content="Bin Cao" name="citation_author"/> <meta content="University of Modena and Reggio Emilia" name="citation_author_institution"/> <meta content="Yahya Shehabi" name="citation_author"/> <meta content="China‐Japan Friendship Hospital, National Clinical Research Center of Respiratory Diseases, Capital Medical University" name="citation_author_institution"/> <meta content="Albertus Beishuizen" name="citation_author"/> <meta content="Jens‐Ulrik S Jensen" name="citation_author"/> <meta content="Medisch Spectrum Twente" name="citation_author_institution"/> <meta content="Caspar Corti" name="citation_author"/> <meta content="Jos A Van Oers" name="citation_author"/> <meta content="Copenhagen University Hospital, Bispebjerg og Frederiksberg" name="citation_author_institution"/> <meta content="Ann R Falsey" name="citation_author"/> <meta content="Elisabeth Tweesteden Ziekenhuis" name="citation_author_institution"/> <meta content="Evelien de Jong" name="citation_author"/> <meta content="University of Rochester School of Medicine" name="citation_author_institution"/> <meta content="Carolina F Oliveira" name="citation_author"/> <meta content="VU University Medical Center" name="citation_author_institution"/> <meta content="Bianca Beghe" name="citation_author"/> <meta content="Federal University of Minas Gerais" name="citation_author_institution"/> <meta content="Matthias Briel" name="citation_author"/> <meta content="AOU Policlinico di Modena" name="citation_author_institution"/> <meta content="Beat Mueller" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD007498.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/10/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007498.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007498.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007498.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Anti-Bacterial Agents [adverse effects, *therapeutic use]; Bacterial Infections [blood, *drug therapy, mortality]; Biomarkers [blood]; Calcitonin [*blood]; Calcitonin Gene-Related Peptide; Cause of Death; Protein Precursors [*blood]; Randomized Controlled Trials as Topic; Respiratory Tract Infections [blood, *drug therapy, mortality]; Treatment Failure" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007498.pub3&amp;doi=10.1002/14651858.CD007498.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007498\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007498\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pt","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007498.pub3",title:"Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections",firstPublishedDate:"Oct 12, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007498.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007498.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007498.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007498.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007498.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007498.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007498.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007498.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007498.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007498.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>19698 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007498.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-sec-0087"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/appendices#CD007498-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/table_n/CD007498StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/table_n/CD007498StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Philipp Schuetz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0003">Yannick Wirz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0004">Ramon Sager</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0005">Mirjam Christ‐Crain</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0006">Daiana Stolz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0007">Michael Tamm</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0008">Lila Bouadma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0009">Charles E Luyt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0010">Michel Wolff</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0011">Jean Chastre</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0012">Florence Tubach</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0013">Kristina B Kristoffersen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0014">Olaf Burkhardt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0015">Tobias Welte</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0016">Stefan Schroeder</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0017">Vandack Nobre</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0018">Long Wei</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0019">Heiner C C Bucher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0020">Neera Bhatnagar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0021">Djillali Annane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0022">Konrad Reinhart</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0023">Angela Branche</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0024">Pierre Damas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0025">Maarten Nijsten</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0026">Dylan W de Lange</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0027">Rodrigo O Deliberato</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0028">Stella SS Lima</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0029">Vera Maravić‐Stojković</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0030">Alessia Verduri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0031">Bin Cao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0032">Yahya Shehabi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0033">Albertus Beishuizen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0034">Jens‐Ulrik S Jensen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0035">Caspar Corti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0036">Jos A Van Oers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0037">Ann R Falsey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0038">Evelien de Jong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0039">Carolina F Oliveira</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0040">Bianca Beghe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0041">Matthias Briel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information#CD007498-cr-0042">Beat Mueller</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information/en#CD007498-sec-0115">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 October 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007498.pub3">https://doi.org/10.1002/14651858.CD007498.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007498-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007498-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007498-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007498-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007498-abs-0002">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007498-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007498-abs-0001" lang="en"> <section id="CD007498-sec-0001"> <h3 class="title" id="CD007498-sec-0001">Background</h3> <p>Acute respiratory infections (ARIs) comprise of a large and heterogeneous group of infections including bacterial, viral, and other aetiologies. In recent years, procalcitonin (PCT), a blood marker for bacterial infections, has emerged as a promising tool to improve decisions about antibiotic therapy (PCT‐guided antibiotic therapy). Several randomised controlled trials (RCTs) have demonstrated the feasibility of using procalcitonin for starting and stopping antibiotics in different patient populations with ARIs and different settings ranging from primary care settings to emergency departments, hospital wards, and intensive care units. However, the effect of using procalcitonin on clinical outcomes is unclear. This is an update of a Cochrane review and individual participant data meta‐analysis first published in 2012 designed to look at the safety of PCT‐guided antibiotic stewardship. </p> </section> <section id="CD007498-sec-0002"> <h3 class="title" id="CD007498-sec-0002">Objectives</h3> <p>The aim of this systematic review based on individual participant data was to assess the safety and efficacy of using procalcitonin for starting or stopping antibiotics over a large range of patients with varying severity of ARIs and from different clinical settings. </p> </section> <section id="CD007498-sec-0003"> <h3 class="title" id="CD007498-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE, and Embase, in February 2017, to identify suitable trials. We also searched ClinicalTrials.gov to identify ongoing trials in April 2017. </p> </section> <section id="CD007498-sec-0004"> <h3 class="title" id="CD007498-sec-0004">Selection criteria</h3> <p>We included RCTs of adult participants with ARIs who received an antibiotic treatment either based on a procalcitonin algorithm (PCT‐guided antibiotic stewardship algorithm) or usual care. We excluded trials if they focused exclusively on children or used procalcitonin for a purpose other than to guide initiation and duration of antibiotic treatment. </p> </section> <section id="CD007498-sec-0005"> <h3 class="title" id="CD007498-sec-0005">Data collection and analysis</h3> <p>Two teams of review authors independently evaluated the methodology and extracted data from primary studies. The primary endpoints were all‐cause mortality and treatment failure at 30 days, for which definitions were harmonised among trials. Secondary endpoints were antibiotic use, antibiotic‐related side effects, and length of hospital stay. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) using multivariable hierarchical logistic regression adjusted for age, gender, and clinical diagnosis using a fixed‐effect model. The different trials were added as random‐effects into the model. We conducted sensitivity analyses stratified by clinical setting and type of ARI. We also performed an aggregate data meta‐analysis. </p> </section> <section id="CD007498-sec-0006"> <h3 class="title" id="CD007498-sec-0006">Main results</h3> <p>From 32 eligible RCTs including 18 new trials for this 2017 update, we obtained individual participant data from 26 trials including 6708 participants, which we included in the main individual participant data meta‐analysis. We did not obtain individual participant data for four trials, and two trials did not include people with confirmed ARIs. According to GRADE, the quality of the evidence was high for the outcomes mortality and antibiotic exposure, and quality was moderate for the outcomes treatment failure and antibiotic‐related side effects. </p> <p>Primary endpoints: there were 286 deaths in 3336 procalcitonin‐guided participants (8.6%) compared to 336 in 3372 controls (10.0%), resulting in a significantly lower mortality associated with procalcitonin‐guided therapy (adjusted OR 0.83, 95% CI 0.70 to 0.99, P = 0.037). We could not estimate mortality in primary care trials because only one death was reported in a control group participant. Treatment failure was not significantly lower in procalcitonin‐guided participants (23.0% versus 24.9% in the control group, adjusted OR 0.90, 95% CI 0.80 to 1.01, P = 0.068). Results were similar among subgroups by clinical setting and type of respiratory infection, with no evidence for effect modification (P for interaction &gt; 0.05). Secondary endpoints: procalcitonin guidance was associated with a 2.4‐day reduction in antibiotic exposure (5.7 versus 8.1 days, 95% CI ‐2.71 to ‐2.15, P &lt; 0.001) and lower risk of antibiotic‐related side effects (16.3% versus 22.1%, adjusted OR 0.68, 95% CI 0.57 to 0.82, P &lt; 0.001). Length of hospital stay and intensive care unit stay were similar in both groups. A sensitivity aggregate‐data analysis based on all 32 eligible trials showed similar results. </p> </section> <section id="CD007498-sec-0007"> <h3 class="title" id="CD007498-sec-0007">Authors' conclusions</h3> <p>This updated meta‐analysis of individual participant data from 12 countries shows that the use of procalcitonin to guide initiation and duration of antibiotic treatment results in lower risks of mortality, lower antibiotic consumption, and lower risk for antibiotic‐related side effects. Results were similar for different clinical settings and types of ARIs, thus supporting the use of procalcitonin in the context of antibiotic stewardship in people with ARIs. Future high‐quality research is needed to confirm the results in immunosuppressed patients and patients with non‐respiratory infections. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007498-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007498-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007498-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007498-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007498-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007498-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007498-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007498-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007498-abs-0004" lang="en"> <h3>Testing blood procalcitonin levels to decide when to start and stop antibiotics in adults with acute respiratory tract infections </h3> <p><b>Review question</b> </p> <p>What are the effects of using procalcitonin to start or discontinue antibiotics in people with acute respiratory infections compared to routine care on mortality and treatment failure? </p> <p><b>Background</b> </p> <p>In people with acute respiratory infections, unnecessary antibiotic use significantly contributes to increasing bacterial resistance, medical costs, and the risk of drug‐related adverse events. The blood marker procalcitonin increases in bacterial infections and decreases when patients recover from the infection. Procalcitonin can be measured in the blood of patients by different commercially available assays with a turnaround time of around one to two hours and support clinical decision making about initiation and discontinuation of antibiotic therapy. </p> <p><b>Search date</b> </p> <p>We conducted electronic searches on 10 February 2017. We conducted searches for ongoing trials on 12 April 2017. </p> <p><b>Study characteristics</b> </p> <p>All included trials randomised participants with acute respiratory infections to receive antibiotics based on procalcitonin levels ('procalcitonin‐guided' group) or a control group. The trials were performed in primary care, the emergency department and medical wards, and the intensive care unit. Included participants had acute upper or lower respiratory infections, including pneumonia, bronchitis, exacerbation of chronic obstructive pulmonary disease, and others. </p> <p><b>Study funding sources</b> </p> <p>All studies were investigator‐initiated trials. Half of the trials were funded by national agencies or did not report funding, and half of the trials received funding from the biomarker industry (e.g. Thermo Fisher Scientific). </p> <p><b>Key results</b> </p> <p>We studied 6708 participants from 26 trials in 12 countries. Mortality at 30 days was significantly lower in procalcitonin‐guided participants compared to control participants (286 deaths in 3336 procalcitonin‐guided participants (8.6%) versus 336 deaths in 3372 controls (10.0%)). There was no significant difference with regard to treatment failures. Results were similar for different clinical settings (primary care, emergency department, intensive care unit) and types of respiratory infection. Regarding antibiotic exposure, participants in the procalcitonin‐guided group had a 2.4‐day reduction in antibiotic exposure and a reduction in antibiotic‐related side effects (16.3% versus 22.1%). </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence was high for mortality and antibiotic exposure. Most of the trials did not use blinding, however we did not expect that mortality would be biased by this limitation. The quality of the evidence was moderate for treatment failure and antibiotic‐related side effects because the definitions for these endpoints among trials were not identical. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007498-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007498-sec-0093"></div> <h3 class="title" id="CD007498-sec-0094">Implications for practice</h3> <section id="CD007498-sec-0094"> <p>Emerging bacterial resistance to multiple antibiotic agents calls for more stringent efforts to reduce the empiric use of antimicrobial agents in self limited and non‐bacterial diseases and to shorten the duration of antibiotic treatment in bacterial infection with clinical resolution. The results of our study suggest that procalcitonin (PCT) is a safe and effective tool to guide clinical decisions for antibiotic initiation and duration of treatment. In all trials, PCT was used to inform physicians about the need for initiation or discontinuation of antibiotic therapy, or both. However, there were differences in PCT protocols among trials depending on the clinical setting (see <a href="#CD007498-tbl-0002">Table 1</a> for details about PCT recommendations used in the individual trials) (<a href="./references#CD007498-bbs2-0088" title="SchuetzP , ChiappaV , BrielM , GreenwaldJL . Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine2011;171(15):1322‐31. ">Schuetz 2011a</a>; <a href="./references#CD007498-bbs2-0089" title="SchuetzP , AujeskyD , MullerC , MullerB . Biomarker‐guided personalised emergency medicine for all ‐ hope for another hype?. Swiss Medical Weekly2015;145:w14079. ">Schuetz 2015</a>). In brief, PCT was mainly used to inform about initiation of antibiotic treatment in primary care trials, and re‐measurement of PCT was recommended in participants not being treated with antibiotics and not showing a resolution of illness at follow‐up. In the emergency room and hospital ward setting, PCT was used to inform about initiation of antibiotic treatment (mainly in low‐risk patients with bronchitis or chronic obstructive pulmonary disease exacerbation), and also about discontinuation of treatment in community‐acquired pneumonia patients. In intensive care unit patients, PCT was mainly used to monitor treatment and discontinue antibiotics in participants with clinical improvement and a drop in PCT levels. Thus for clinical practice, PCT should also be adapted to clinical settings and the risk of patients ‐ similar to patients with suspicion of pulmonary embolism where D‐dimer levels are used differently depending on the pre‐test probability (<a href="./references#CD007498-bbs2-0072" title="KonstantinidesS . Clinical practice. Acute pulmonary embolism. New England Journal of Medicine2008;359(26):2804‐13. ">Konstantinides 2008</a>). </p> <p>The use of PCT to guide initiation and duration of antibiotic treatment in people with acute respiratory infections (ARIs) was associated with lower mortality rates and significantly reduced antibiotic consumption and associated side effects across different clinical settings and ARI diagnoses. Of note, mortality was very low in primary care patients, and we were thus not able to assess the effect of PCT on mortality. The use of PCT embedded in clinical algorithms has the potential to improve the antibiotic management of ARI patients and has substantial clinical and public health implications to reduce antibiotic exposure and the associated risk of antibiotic resistance. Several assays for the measurement of PCT are currently available (<a href="./references#CD007498-bbs2-0091" title="SchuetzP , BirkhahnR , SherwinR , JonesAE , SingerA , KlineJA , et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin monitoring sepsis (MOSES) study. Critical Care Medicine2017;45(5):781‐9. ">Schuetz 2017</a>), and the US Food and Drug Administration recently cleared the Vidas assay, among others, for antibiotic stewardship and prognostication of patients using a PCT kinetics algorithm (<a href="./references#CD007498-bbs2-0090" title="SchuetzP , DanielsLB , KulkarniP , AnkerSD , MuellerB . Procalcitonin: a new biomarker for the cardiologist. International Journal of Cardiology2016;223:390‐7. [DOI: 10.1016/j.ijcard.2016.08.204] ">Schuetz 2016</a>). Importantly, all trials have used highly sensitive assays to measure PCT in order to have optimal sensitivity and thus test performance. Factors such as accessibility and time taken to get reports of the tests are equally important in whether PCT will be used in the clinical decision‐making process for antibiotic therapy in ARIs. In this regard, a point‐of‐care test would be important, especially for the primary care setting (<a href="./references#CD007498-bbs2-0076" title="KutzK , HausfaterP , OppertM , AlanM , GrolimundE , GastC , et al. Comparison between B·R·A·H·M·S PCT direct, a new sensitive point‐of‐care testing device for rapid quantification of procalcitonin in emergency department patients and established reference methods ‐ a prospective multinational trial. Clinical Chemistry and Laboratory Medicine2016;54(4):577‐84. ">Kutz 2016</a>). </p> <p>Importantly, all trials included PCT into clinical algorithms, and physicians could deviate from the PCT algorithm if needed. Poststudy surveys have been published in order to better understand the effects and challenges of PCT testing in clinical practice (<a href="./references#CD007498-bbs2-0057" title='AlbrichWC , DusemundF , BucherB , MeyerS , ThomannR , KuhnF , et al. Effectiveness and safety of procalcitonin‐guided antibiotic therapy in lower respiratory tract infections in "real life": an international, multicenter post‐study survey (ProREAL). Archives of Internal Medicine2012;172(9):715‐22. '>Albrich 2012</a>; <a href="./references#CD007498-bbs2-0060" title="BalkRA , KadriSS , CaoZ , RobinsonSB , LipkinC , BozzetteSA . Effect of procalcitonin testing on health‐care utilization and costs in critically ill patients in the United States. Chest2017;151(1):23‐33. ">Balk 2017</a>).  </p> </section> <h3 class="title" id="CD007498-sec-0095">Implications for research</h3> <section id="CD007498-sec-0095"> <p>Future studies should establish cost‐effectiveness by considering country‐specific costs of PCT measurement (around USD 20 to USD 30 per sample) and potential savings in consumption of antibiotics and other healthcare resources (<a href="./references#CD007498-bbs2-0095" title="StojanovicI , SchneiderJE , WeiL , HongZ , KeaneC , SchuetzP . Economic evaluation of procalcitonin‐guided antibiotic therapy in acute respiratory infections: a Chinese hospital system perspective. Clinical Chemistry and Laboratory Medicine2017;55(4):561‐70. ">Stojanovic 2017</a>).  </p> <p>In addition, it would be interesting to conduct a head‐to‐head trial comparing a PCT strategy to a strategy based on another biomarker, such as C‐reactive protein (CRP) or interleukin‐6 (<a href="./references#CD007498-bbs2-0081" title="MeiliM , MullerB , KulkarniP , SchutzP . Management of patients with respiratory infections in primary care: procalcitonin, C‐reactive protein or both?. Expert Review of Respiratory Medicine2015;9(5):587‐601. ">Meili 2015</a>; <a href="./references#CD007498-bbs2-0082" title="MeiliM , KutzA , BrielM , Christ‐CrainM , BucherHC , MuellerB , et al. Infection biomarkers in primary care patients with acute respiratory tract infections ‐ comparison of procalcitonin and C‐reactive protein. BMC Pulmonary Medicine2016;16(1):43. ">Meili 2016</a>). A similar randomised controlled trial was recently conducted in primary care in the Netherlands with a treatment algorithm based on either CRP levels, communication training, or both, compared to a control group (<a href="./references#CD007498-bbs2-0061" title="CalsJW , ButlerCC , HopstakenRM , HoodK , DinantGJ . Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ2009;338:b1374. ">Cals 2009</a>). The trial authors reported a 42% relative reduction in antibiotic use with CRP guidance, which was similar to the effect of communication training in this setting. However, the usefulness of CRP for antibiotic guidance outside the primary care setting is not yet supported by controlled intervention trials. </p> <p>While there is strong evidence for the use of PCT in respiratory infections, its role in other infections remains unclear. Several studies have investigated PCT as a diagnostic and antibiotic stewardship marker in different types of infections (<a href="./references#CD007498-bbs2-0057" title='AlbrichWC , DusemundF , BucherB , MeyerS , ThomannR , KuhnF , et al. Effectiveness and safety of procalcitonin‐guided antibiotic therapy in lower respiratory tract infections in "real life": an international, multicenter post‐study survey (ProREAL). Archives of Internal Medicine2012;172(9):715‐22. '>Albrich 2012</a>; <a href="./references#CD007498-bbs2-0063" title="DrozdovD , SchwarzS , KutzA , GrolimundE , RastAC , SteinerD , et al. Procalcitonin and pyuria‐based algorithm reduces antibiotic use in urinary tract infections: a randomized controlled trial. BMC Medicine2015;13(1):104. ">Drozdov 2015</a>; <a href="./references#CD007498-bbs2-0087" title="SagerR , KutzA , MuellerB , SchuetzP . Procalcitonin‐guided diagnosis and antibiotic stewardship revisited. BMC Medicine2017;15(1):15. ">Sager 2017</a>). However, larger trials powered for safety are needed to understand the effect of PCT outside respiratory infections. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007498-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007498-sec-0029"></div> <div class="table" id="CD007498-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Procalcitonin algorithm compared to standard care for guiding antibiotic therapy in acute respiratory tract infections</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Procalcitonin algorithm compared to standard care for guiding antibiotic therapy in acute respiratory tract infections</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with acute respiratory tract infections<br/> <b>Settings:</b> primary care, emergency department, intensive care unit<br/> <b>Intervention:</b> PCT‐guided care<br/> <b>Comparison:</b> standard care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Standard care</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>PCTalgorithm</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: 30 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.83</b><br/> (0.70 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6708<br/> (26 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b> </p> <p>(76 to 95)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment failure</b><br/> Clinical assessment<sup>3</sup><br/> Follow‐up: 30 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.90</b> <br/> (0.80 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6708<br/> (26 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>249 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1000</b> </p> <p>(216 to 245)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic‐related side effects</b> </p> <p>Follow‐up: 30 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Study population</b> </p> <p><b>221 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>163 per 1000</b> </p> <p>(145 to 182)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.68</b> <br/> (0.57 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3034<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic exposure</b><br/> Total days of antibiotic therapy in all randomised participants </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean antibiotic exposure in the control groups was<br/> <b>8.1 days</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean antibiotic exposure in the intervention groups was<br/> 2.43 days<b>lower</b><br/> (2.15 to 2.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6708<br/> (26 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio: <b>PCT:</b> procalcitonin </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No downgrading for serious concerns. Still, there is some concern about unconcealed allocation in several trials in the emergency department and intensive care settings. There is also some concern about low adherence with the PCT algorithm in the intervention group. We consider unblinded outcome assessment as not relevant for the outcome of death.<br/> <sup>2</sup>Downgraded one level for serious inconsistency: trials used differing definition of treatment failure and some rare events were not systematically assessed among trials.<br/> <sup>3</sup>For the primary care setting, treatment failure was defined as death, hospitalisation, acute respiratory infection (ARI)‐specific complications (e.g. empyema for lower ARI, meningitis for upper ARI), recurrent or worsening infection, and participants reporting any symptoms of an ongoing respiratory infection (e.g. fever, cough, dyspnoea) at follow‐up. For the emergency department setting, treatment failure was defined as death, intensive care unit (ICU) admission, rehospitalisation after index hospital discharge, ARI‐associated complications (e.g. empyema or acute respiratory distress syndrome for lower ARI), and recurrent or worsening infection within 30 days of follow‐up. For the ICU setting, treatment failure was defined as death within 30 days of follow‐up.<br/> <sup>4</sup>Downgraded one level for incomplete reporting: only 6 trials reported side effects from antibiotics, and none of these trials were conducted in the ICU setting. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007498-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007498-sec-0030"></div> <p>Acute respiratory infections (ARIs) account for over 10% of global disease burden and are the most common reason for antibiotic therapy in primary care and hospital settings (<a href="./references#CD007498-bbs2-0064" title="EvansAT , HusainS , DurairajL , SadowskiLS , Charles‐DamteM , WangY . Azithromycin for acute bronchitis: a randomised, double‐blind, controlled trial. Lancet2002;359(9318):1648‐54. ">Evans 2002</a>; <a href="./references#CD007498-bbs2-0065" title="GonzalesR , SteinerJF , SandeMA . Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA1997;278(11):901‐4. ">Gonzales 1997</a>; <a href="./references#CD007498-bbs2-0100" title="ZaasAK , GarnerBH , TsalikEL , BurkeT , WoodsCW , GinsburgGS . The current epidemiology and clinical decisions surrounding acute respiratory infections. Trends in Molecular Medicine2014;20(10):579‐88. ">Zaas 2014</a>). </p> <section id="CD007498-sec-0031"> <h3 class="title" id="CD007498-sec-0031">Description of the condition</h3> <p>Acute respiratory infections comprise a heterogeneous group of infections including bacterial, viral, and other aetiologies. As many as 75% of all antibiotic doses are prescribed for ARIs, despite their mainly viral cause (<a href="./references#CD007498-bbs2-0062" title="DoanQ , EnarsonP , KissoonN , KlassenTP , JohnsonDW . Rapid viral diagnosis for acute febrile respiratory illness in children in the Emergency Department. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006452.pub4] ">Doan 2014</a>; <a href="./references#CD007498-bbs2-0064" title="EvansAT , HusainS , DurairajL , SadowskiLS , Charles‐DamteM , WangY . Azithromycin for acute bronchitis: a randomised, double‐blind, controlled trial. Lancet2002;359(9318):1648‐54. ">Evans 2002</a>). Early initiation of adequate antibiotic therapy is the cornerstone in the treatment of bacterial ARIs and is associated with improved clinical outcomes (<a href="./references#CD007498-bbs2-0070" title="HoareZ , LimWS . Pneumonia: update on diagnosis and management. BMJ2006;332(7549):1077‐9. ">Hoare 2006</a>; <a href="./references#CD007498-bbs2-0073" title="KumarA , RobertsD , WoodKE , LightB , ParrilloJE , SharmaS , et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Medicine2006;34(6):1589‐96. ">Kumar 2006</a>; <a href="./references#CD007498-bbs2-0074" title="KumarA , EllisP , ArabiY , RobertsD , LightB , ParrilloJE , et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest2009;136(5):1237‐48. ">Kumar 2009</a>; <a href="./references#CD007498-bbs2-0079" title="LiberatiA , D'AmicoR , PifferiS , TorriV , BrazziL , ParmelliE . Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000022.pub3] ">Liberati 2009b</a>; <a href="./references#CD007498-bbs2-0092" title="SpurlingGKP , DelMarCB , DooleyL , FoxleeR . Delayed antibiotics for respiratory infections. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD004417.pub3] ">Spurling 2010</a>). However, overuse of antibiotics by overprescription in outpatients with bronchitis (<a href="./references#CD007498-bbs2-0058" title="ArnoldSR , StrausSE . Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003539.pub2] ">Arnold 2005</a>), for instance, and prolonged duration of antibiotic therapy in people with bacterial ARIs in the hospital and intensive care unit (ICU) settings is associated with increased resistance to common bacteria, high costs, and adverse drug reactions (<a href="./references#CD007498-bbs2-0065" title="GonzalesR , SteinerJF , SandeMA . Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA1997;278(11):901‐4. ">Gonzales 1997</a>; <a href="./references#CD007498-bbs2-0066" title="GoossensH , FerechM , Vander SticheleR , ElseviersM . Outpatient antibiotic use in Europe and association with resistance: a cross‐national database study. Lancet2005;365(9435):579‐87. ">Goossens 2005</a>; <a href="./references#CD007498-bbs2-0077" title="LawrenceKL , KollefMH . Antimicrobial stewardship in the intensive care unit: advances and obstacles. American Journal of Respiratory and Critical Care Medicine2009;179(6):434‐8. ">Lawrence 2009</a>; <a href="./references#CD007498-bbs2-0100" title="ZaasAK , GarnerBH , TsalikEL , BurkeT , WoodsCW , GinsburgGS . The current epidemiology and clinical decisions surrounding acute respiratory infections. Trends in Molecular Medicine2014;20(10):579‐88. ">Zaas 2014</a>). </p> </section> <section id="CD007498-sec-0032"> <h3 class="title" id="CD007498-sec-0032">Description of the intervention</h3> <p>The presence of a diagnostic 'gold standard' or reference standard represents the best available method for establishing the presence or absence of a disease. Optimally, a morphological verification such as histopathology or, in the case of ARIs, growth of typical pathogens in blood cultures or sputum cultures can be obtained to establish the 'correct' diagnosis. Regrettably, the use of blood cultures as the assumed gold standard in ARIs lacks sensitivity, specificity, or both, with only around 10% of people with pneumonia having positive cultures and some of them being false positives (<a href="./references#CD007498-bbs2-0085" title="MullerF , Christ‐CrainM , BregenzerT , KrauseM , ZimmerliW , MuellerB , et al. Procalcitonin levels predict bacteremia in patients with community‐acquired pneumonia: a prospective cohort trial. Chest2010;138(1):121‐9. ">Muller 2010</a>). In this diagnostic uncertainty, surrogate biomarker to estimate the likelihood for the presence of a bacterial infection and to grade disease severity are of great interest (<a href="./references#CD007498-bbs2-0089" title="SchuetzP , AujeskyD , MullerC , MullerB . Biomarker‐guided personalised emergency medicine for all ‐ hope for another hype?. Swiss Medical Weekly2015;145:w14079. ">Schuetz 2015</a>). In such a circumstance, two fundamentally different concepts are employed. One concept tends to ignore potential dilemmas in the accuracy of the alleged gold standard but assumes a well‐defined illness, which is represented by the assumption drawn following a diagnostic test or a clinical diagnosis. The second concept discards alleged gold standards and focuses on patient outcomes. In the case of ARIs, the clinical benefit of a diagnostic biomarker, such as procalcitonin (PCT), can be measured by clinical outcomes of randomised intervention studies, assuming that if the person recovered without antibiotics then there was no relevant bacterial illness. </p> <p>In recent years, PCT has emerged as a promising marker for the diagnosis of bacterial infections because higher levels are found in severe bacterial infections but remain fairly low in viral infections and non‐specific inflammatory diseases (<a href="./references#CD007498-bbs2-0083" title="MullerB , BeckerKL , SchachingerH , RickenbacherPR , HuberPR , ZimmerliW , et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Critical Care Medicine2000;28(4):977‐83. ">Muller 2000</a>; <a href="./references#CD007498-bbs2-0084" title="MullerB , BeckerKL . Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss Medical Weekly2001;131(41‐2):595‐602. ">Muller 2001</a>; <a href="./references#CD007498-bbs2-0085" title="MullerF , Christ‐CrainM , BregenzerT , KrauseM , ZimmerliW , MuellerB , et al. Procalcitonin levels predict bacteremia in patients with community‐acquired pneumonia: a prospective cohort trial. Chest2010;138(1):121‐9. ">Muller 2010</a>). Procalcitonin is released in multiple tissues in response to bacterial infections via a direct stimulation of cytokines, such as interleukin (IL)‐1β, tumour necrosis factor (TNF)‐ɑ, and IL‐6. Conversely, PCT production is blocked by interferon gamma, a cytokine released in response to viral infections (<a href="./references#CD007498-bbs2-0083" title="MullerB , BeckerKL , SchachingerH , RickenbacherPR , HuberPR , ZimmerliW , et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Critical Care Medicine2000;28(4):977‐83. ">Muller 2000</a>). Hence, PCT may be used to support clinical decision making for the initiation and discontinuation of antibiotic therapy in different types of infections and indications (<a href="./references#CD007498-bbs2-0087" title="SagerR , KutzA , MuellerB , SchuetzP . Procalcitonin‐guided diagnosis and antibiotic stewardship revisited. BMC Medicine2017;15(1):15. ">Sager 2017</a>; <a href="./references#CD007498-bbs2-0090" title="SchuetzP , DanielsLB , KulkarniP , AnkerSD , MuellerB . Procalcitonin: a new biomarker for the cardiologist. International Journal of Cardiology2016;223:390‐7. [DOI: 10.1016/j.ijcard.2016.08.204] ">Schuetz 2016</a>). Randomised controlled trials (RCTs) have demonstrated the feasibility of such a strategy in different ARI patient populations and different settings ranging from primary care to emergency departments and hospital wards to medical and surgical ICUs (<a href="./references#CD007498-bbs2-0002" title="BloosF , TripsE , NierhausA , BriegelJ , HeylandDK , JaschinskiU , et al. Effect of sodium selenite administration and procalcitonin‐guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Internal Medicine2016;176(9):1266‐76. ">Bloos 2016</a>; <a href="./references#CD007498-bbs2-0004" title="BrancheAR , WalshEE , VargasR , HulbertB , FormicaMA , BaranA , et al. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. Journal of Infectious Diseases2015;212(11):1692‐700. ">Branche 2015</a>; <a href="./references#CD007498-bbs2-0009" title="CortiC , FallyM , Fabricius‐BjerreA , MortensenK , JensenBN , AndreassenHF , et al. Point‐of‐care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. International Journal of Chronic Obstructructive Pulmonary Disease2016;11:1381‐9. [DOI: 10.2147/COPD.S104051] ">Corti 2016</a>; <a href="./references#CD007498-bbs2-0010" title="DeJongE , vanOersJA , BeishuizenA , VosP , VermeijdenWJ , HaasLE , et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open‐label trial. Lancet Infectious Diseases2016;16(7):819‐27. ">De Jong 2016</a>; <a href="./references#CD007498-bbs2-0011" title="DeliberatoRO , MarraAR , SanchesPR , MartinoMD , FerreiraCE , PasternakJ , et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagnostic Microbiology and Infectious Disease2013;76(3):266‐71. ">Deliberato 2013</a>; <a href="./references#CD007498-bbs2-0015" title="LayiosN , LambermontB , CanivetJL , MorimontP , PreiserJC , GarwegC , et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Critical Care Medicine2012;40(8):2304‐9. ">Layios 2012</a>; <a href="./references#CD007498-bbs2-0019" title="LongW , LiLJ , HuangGZ , ZhangXM , ZhangYC , TangJG , et al. Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12‐month follow‐up. Critical Care2014;18(5):471. ">Long 2014</a>; <a href="./references#CD007498-bbs2-0020" title="Maravić‐StojkovićV , Laušević‐VukL , JovićM , RankovićA , BorzanovićM , MarinkovićJ . Procalcitonin‐based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: a randomized controlled trial. Srpski Arhiv Celokupno Lekarstvo2011;139(11‐12):736‐42. ">Maravić‐Stojković 2011</a>; <a href="./references#CD007498-bbs2-0024" title="OliveiraCF , BotoniFA , OliveiraCR , SilvaCB , PereiraHA , SerufoJC , et al. Procalcitonin versus C‐reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Critical Care Medicine2013;41(10):2336‐43. ">Oliveira 2013</a>; <a href="./references#CD007498-bbs2-0027" title="ShehabiY , SterbaM , GarrettPM , RachakondaKS , StephensD , HarriganP , et al. ProGUARD Study Investigators, ANZICS Clinical Trials Group. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2014;190(10):1102‐10. ">Shehabi 2014</a>; <a href="./references#CD007498-bbs2-0031" title="VerduriA , LuppiF , D'AmicoR , BalduzziS , ViciniR , LiveraniA , et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS ONE2015;10(3):e0118241. ">Verduri 2015</a>; <a href="./references#CD007498-bbs2-0032" title="WangJX , ZhangSM , LiXH , ZhangY , XuZY , CaoB . Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. International Journal of Infectious Diseases2016;48:40‐5. [DOI: 10.1016/j.ijid.2016.04.024] ">Wang 2016</a>). </p> </section> <section id="CD007498-sec-0033"> <h3 class="title" id="CD007498-sec-0033">How the intervention might work</h3> <p>Procalcitonin levels correlate with the risk of relevant bacterial infections and decrease upon recovery. Procalcitonin testing may therefore help physicians decide in which patients antibiotics are needed and when it is safe to stop treatment (<a href="./references#CD007498-bbs2-0075" title="KutzA , BrielM , Christ‐CrainM , StolzD , BouadmaL , WolffM , et al. Prognostic value of procalcitonin in respiratory tract infections across clinical settings. Critical Care (London, England)2015;19(1):74. ">Kutz 2015</a>). The use of PCT in clinical protocols may thus decrease antibiotic consumption in two ways: by preventing unnecessary antibiotic prescriptions and by limiting durations of antibiotic treatment (<a href="./references#CD007498-bbs2-0087" title="SagerR , KutzA , MuellerB , SchuetzP . Procalcitonin‐guided diagnosis and antibiotic stewardship revisited. BMC Medicine2017;15(1):15. ">Sager 2017</a>; <a href="./references#CD007498-bbs2-0088" title="SchuetzP , ChiappaV , BrielM , GreenwaldJL . Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine2011;171(15):1322‐31. ">Schuetz 2011a</a>). </p> </section> <section id="CD007498-sec-0034"> <h3 class="title" id="CD007498-sec-0034">Why it is important to do this review</h3> <p>While several RCTs have evaluated PCT‐guided antibiotic treatment, most individual trials included participants with different types of respiratory and non‐respiratory infections and lacked the statistical power to assess the risk for mortality and severe infectious disease complications associated with PCT‐guided decision making. Previous meta‐analyses of RCTs investigating the effect of PCT algorithms on antibiotic use focused on the critical care setting, people with suspicion of bacterial infections, and people with sepsis and respiratory infections (<a href="./references#CD007498-bbs2-0035" title="HeylandDK , JohnsonAP , ReynoldsSC , MuscedereJ . Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Critical Care Medicine2011;39(7):1792‐9. ">Heyland 2011</a>; <a href="./references#CD007498-bbs2-0071" title="HoeboerSH , van derGeestPJ , NieboerD , GroeneveldAB . The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta‐analysis. Clinical Microbiology and Infection2015;21(5):474‐81. ">Hoeboer 2015</a>; <a href="./references#CD007498-bbs2-0048" title="TangH , HuangT , JingJ , ShenH , CuiW . Effect of procalcitonin‐guided treatment in patients with infections: a systematic review and meta‐analysis. Infection2009;37(6):497‐507. ">Tang 2009</a>; <a href="./references#CD007498-bbs2-0099" title="WackerC , PrknoA , BrunkhorstFM , SchlattmannP . Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta‐analysis. Lancet Infectious Diseases2013;13(5):426‐35. ">Wacker 2013</a>). However, these meta‐analyses used aggregated data and were not able to investigate the effects of PCT on different ARI diagnoses and on outcomes other than mortality. A previous meta‐analysis based on individual participant data published in the Cochrane Library did not find a significant difference in clinical outcomes, but confidence intervals remained relatively wide (<a href="./references#CD007498-bbs2-0104" title="SchuetzP , MullerB , Christ‐CrainM , StolzD , TammM , BouadmaL , et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD007498.pub2] ">Schuetz 2012</a>). Safety of using PCT for antibiotic decision making remained thus unproven. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007498-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007498-sec-0035"></div> <p>The aim of this systematic review based on individual participant data was to assess the safety and efficacy of using procalcitonin for starting or stopping antibiotics over a large range of patients with varying severity of ARIs and from different clinical settings. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007498-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007498-sec-0036"></div> <section id="CD007498-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007498-sec-0038"> <h4 class="title">Types of studies</h4> <p>Prospective RCTs comparing a strategy to initiate or discontinue antibiotic therapy based on PCT levels with a control arm without PCT measurements were eligible for inclusion. Participants were randomised to receive antibiotics either based on PCT levels ('PCT‐guided' group) or a control group without knowledge of PCT levels, including antibiotic management based on usual care or guidelines. We did not include non‐randomised studies. </p> </section> <section id="CD007498-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included adult participants with clinical diagnoses of ARIs: either a lower ARI including community‐acquired pneumonia (CAP), hospital‐acquired pneumonia (HAP), ventilator‐associated pneumonia (VAP), acute bronchitis, exacerbation of asthma, or exacerbation of chronic obstructive pulmonary disease (COPD); or an upper ARI including common cold, rhino‐sinusitis, pharyngitis, tonsillitis, or otitis media. We also included people with sepsis and suspected ARIs in the analyses. We excluded trials if they focused exclusively on children or used PCT to escalate antibiotic therapy. We made no exclusions based on language of reports or clinical setting. We included trials from primary care, emergency departments, and medical and surgical ICUs. </p> </section> <section id="CD007498-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Strategies to initiate or discontinue antibiotic therapy based on PCT levels compared with usual care were eligible. </p> </section> <section id="CD007498-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We defined primary and secondary outcomes to a follow‐up time of 30 days. For trials with shorter follow‐up periods, we used the available information (i.e. until hospital discharge). We excluded all trials with different follow‐up times for mortality in a sensitivity analysis. </p> <section id="CD007498-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD007498-list-0001"> <li> <p>All‐cause mortality following randomisation up to a follow‐up time of 30 days.</p> </li> <li> <p>Setting‐specific treatment failure within 30 days of inclusion.</p> </li> </ol> </p> <p>For the primary care setting, we defined treatment failure as death, hospitalisation, ARI‐specific complications (e.g. empyema for lower ARIs, meningitis for upper ARIs), recurrent or worsening infection, and still having ARI‐associated discomfort at 30 days. For the emergency department setting, we defined treatment failure as death, ICU admission, rehospitalisation after index hospital discharge, ARI‐associated complications (e.g. empyema or acute respiratory distress syndrome for lower ARIs), and recurrent or worsening infection within 30 days of follow‐up. For the medical and surgical ICU setting, we defined treatment failure as death within 30 days of follow‐up and recurrent or worsening infection. </p> </section> <section id="CD007498-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD007498-list-0002"> <li> <p>Antibiotic use (initiation of antibiotics, duration of antibiotics, and total exposure to antibiotics (total amount of antibiotic days divided by total number of participants)). </p> </li> <li> <p>Length of hospital stay for hospitalised participants.</p> </li> <li> <p>Length of ICU stay for critically ill participants.</p> </li> <li> <p>Number of days with restricted activities within 14 days after randomisation for primary care participants. </p> </li> <li> <p>Antibiotic‐related side effects.</p> </li> </ol> </p> </section> </section> </section> <section id="CD007498-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>We updated the search strategy for this review in February 2017 in collaboration with the Cochrane Acute Respiratory Infections Group's Information Specialist. We performed data collection based on the protocol of a previous meta‐analysis of individual participant data published in the Cochrane Library (<a href="./references#CD007498-bbs2-0101" title="SchuetzP , BrielM , Christ‐CrainM , WolbersM , StolzD , TammM , et al. Procalcitonin to initiate or withhold antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews2008, Issue 10. [DOI: 10.1002/14651858.CD007498] ">Schuetz 2008</a>). </p> <section id="CD007498-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We updated the searches for this review in February 2017, running the search across all databases from the date of inception to 10 February 2017. We screened all new references identified by the search. We searched the following databases for published studies: </p> <p> <ul id="CD007498-list-0003"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1), part of the Cochrane Library, which includes the Cochrane Acute Respiratory Infections Group's Specialised Register, <a href="http://www.cochranelibrary.com/" target="_blank">www.cochranelibrary.com/</a> (accessed 10 February 2017) (<a href="./appendices#CD007498-sec-0099">Appendix 1</a>); </p> </li> <li> <p>MEDLINE Ovid (1966 to 10 February 2017) (<a href="./appendices#CD007498-sec-0100">Appendix 2</a>); </p> </li> <li> <p>Embase.com (1980 to 10 February 2017) (<a href="./appendices#CD007498-sec-0101">Appendix 3</a>). </p> </li> </ul> </p> <p>We used the search strategy in <a href="./appendices#CD007498-sec-0102">Appendix 4</a> to conduct searches for the 2012 version of this review (<a href="./references#CD007498-bbs2-0104" title="SchuetzP , MullerB , Christ‐CrainM , StolzD , TammM , BouadmaL , et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD007498.pub2] ">Schuetz 2012</a>). </p> <p>We also searched for ongoing and completed trials in the following trial register:</p> <p> <ul id="CD007498-list-0004"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>; searched 12 April 2017). </p> </li> </ul> </p> <p>We did not apply any language or publication restrictions.</p> </section> <section id="CD007498-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We contacted experts for further eligible trials.</p> </section> </section> <section id="CD007498-sec-0047"> <h3 class="title" id="CD007498-sec-0047">Data collection and analysis</h3> <p>We requested individual participant data from the investigators of all included trials. We checked all provided data against published reports, and if needed, corrected any discrepancies. </p> <p>We prepared this review update according to PRISMA guidelines and the PRISMA‐IPD guideline (<a href="./references#CD007498-bbs2-0078" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology2009;62(10):e1‐34. ">Liberati 2009a</a>; <a href="./references#CD007498-bbs2-0094" title="StewartLA , ClarkeM , RoversM , RileyRD , SimmondsM , StewartG , et al. Preferred reporting items for systematic review and meta‐analyses of individual participant data: the PRISMA‐IPD Statement. JAMA2015;313(16):1657‐65. ">Stewart 2015</a>). </p> <section id="CD007498-sec-0048"> <h4 class="title">Selection of studies</h4> <p>At least two review authors (RS, YW, PS) independently assessed trial eligibility based on titles, abstracts, full‐text reports, and further information from investigators as needed. </p> </section> <section id="CD007498-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>We checked data from each trial against reported results and resolved any queries with the principal investigator, trial data manager, or statistician. The mortality and adverse outcome rates from trials included in this review may differ slightly from previous reports because we treated data in a consistent manner across all trials. </p> </section> <section id="CD007498-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RS, YW) assessed the methodological quality of each included study using the Cochrane 'Risk of bias' tool and resolved any disagreements by discussion (<a href="./references#CD007498-bbs2-0069" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Methodological criteria included: adequate sequence generation and concealment of treatment allocation; blinding of participants, physicians and clinical outcome assessment; whether the study was free of selective reporting; and the proportion of participants lost to follow‐up. We documented the proportion of participants in the PCT group that adhered to the PCT algorithm used in each study, defining adherence to the PCT algorithm of lower than 70% as high risk of bias, and, if not reported, as unclear risk. Due to the study design of the included studies, physicians were aware of the participants' study group because in the intervention group physicians used the PCT result for decision making about antibiotic treatment, while in the control group no PCT result was communicated to the physicians. Blinding of physicians was therefore not feasible, resulting in an unclear risk for performance bias in all studies. </p> <p>We assessed the quality of evidence at the outcome level using the GRADE approach (<a href="./references#CD007498-bbs2-0067" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version (accessed April 2017). Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>). </p> </section> <section id="CD007498-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated odds ratios (ORs) and 95% confidence intervals (CIs) using multivariable hierarchical logistic regression for the co‐primary endpoints of mortality from any cause and treatment failure (<a href="./references#CD007498-bbs2-0096" title="ThompsonSG , TurnerRM , WarnDE . Multilevel models for meta‐analysis, and their application to absolute risk differences. Statistical Methods in Medical Research2001;10(6):375‐92. ">Thompson 2001</a>; <a href="./references#CD007498-bbs2-0097" title="TurnerRM , OmarRZ , YangM , GoldsteinH , ThompsonSG . A multilevel model framework for meta‐analysis of clinical trials with binary outcomes. Statistics in Medicine2000;19(24):3417‐32. ">Turner 2000</a>). We fitted corresponding linear and logistic regression models for continuous and binary secondary endpoints, respectively. We calculated Kaplan‐Meier curves for time to death for graphical display. </p> <p>We used Stata version 12.1 (College Station, TX) for statistical analyses (<a href="./references#CD007498-bbs2-0093" title="StataCorp LP. Stata Statistical Software: Release 12.1.. College Station (TX): StataCorp LP, 2005. ">Stata 12.1</a>). </p> </section> <section id="CD007498-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of our primary analysis was the individual study participant. We analysed all participants in the study group to which they were randomised. We calculated summary estimates using aggregated data from individual trials as a sensitivity analysis. </p> </section> <section id="CD007498-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We received the full data sets from all trials included in the individual participant data analysis (n = 26) with all available follow‐up information (if recorded in the trials). </p> <p>We assumed in our main analysis that participants lost to follow‐up did not experience an event. We explored if a complete‐case analysis (excluding participants lost to follow‐up) or an analysis assuming that participants lost to follow‐up experienced an event would change the results for the primary outcomes of mortality and treatment failure in sensitivity analyses. We checked all individual participant data against the published results but did not find significant differences that warranted further exploration. </p> </section> <section id="CD007498-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We performed prespecified analyses stratified by clinical setting (i.e. primary care, emergency department, ICU) and ARI diagnosis (CAP, COPD, bronchitis, VAP) to investigate the consistency of results across our heterogeneous patient populations in terms of disease severity. We formally tested for potential subgroup effects by adding the clinical setting and ARI diagnosis in turn to the regression model together with the corresponding interaction term with the PCT group as a fixed‐effect model. We assessed heterogeneity by estimating the I<sup>2</sup> statistic (the percentage of total variance across trials that is due to heterogeneity rather than chance) in meta‐analyses using aggregated data and by testing for heterogeneity using the Cochran Q test (<a href="./references#CD007498-bbs2-0068" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). </p> </section> <section id="CD007498-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting bias by attempting to identify if the study was included in a trial registry, a protocol was available, and if the methods section provided a list of outcomes. We compared listed outcomes from those sources to outcomes reported in the published papers. </p> </section> <section id="CD007498-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We used multivariable hierarchical logistic regression to combine participant data from the trials (<a href="./references#CD007498-bbs2-0096" title="ThompsonSG , TurnerRM , WarnDE . Multilevel models for meta‐analysis, and their application to absolute risk differences. Statistical Methods in Medical Research2001;10(6):375‐92. ">Thompson 2001</a>; <a href="./references#CD007498-bbs2-0097" title="TurnerRM , OmarRZ , YangM , GoldsteinH , ThompsonSG . A multilevel model framework for meta‐analysis of clinical trials with binary outcomes. Statistics in Medicine2000;19(24):3417‐32. ">Turner 2000</a>). Apart from the group variable indicating the use of a PCT algorithm, we included important prognostic factors such as participant age and ARI diagnosis as an additional fixed effect; to account for within‐ and between‐trial variability, we added a categorical trial variable to the model as a random effect. In meta‐analyses with aggregated trial data we calculated summary ORs using a random‐effects model and the Mantel‐Haenszel facility of Review Manager 5 (<a href="./references#CD007498-bbs2-0086" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <section id="CD007498-sec-0057"> <h5 class="title">GRADE and 'Summary of findings' table</h5> <p>We created a 'Summary of findings' table using the following outcomes: all‐cause mortality at 30 days, setting‐specific treatment failure at 30 days, total exposure to antibiotics, and antibiotic‐related side effects (<a href="./full#CD007498-tbl-0001">summary of findings Table for the main comparison</a>)<i>.</i> The results reported in this table correspond to the main IPD analysis and are slightly different from the aggregate data analysis. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies that contribute data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD007498-bbs2-0059" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">Atkins 2004</a>). We used the methods and recommendations in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007498-bbs2-0069" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), employing GRADEpro GDT software (<a href="./references#CD007498-bbs2-0067" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version (accessed April 2017). Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>). We justified all decisions to down‐ or upgrade the quality of studies using footnotes, and we made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> <section id="CD007498-sec-0058"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed prespecified analyses stratified by clinical setting and ARI diagnosis and formally tested for potential subgroup effects by adding an interaction term into the statistical model. </p> </section> <section id="CD007498-sec-0059"> <h4 class="title">Sensitivity analysis</h4> <p>We performed prespecified sensitivity analyses based on the main quality indicators: allocation concealment, blinded outcome assessment, adherence to the PCT algorithm (we defined low adherence to PCT algorithms as &lt; 70%), and follow‐up time for mortality other than one month. We also performed an aggregate data meta‐analysis using all trials with potentially eligible participants. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007498-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007498-sec-0060"></div> <section id="CD007498-sec-0061"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD007498-sec-0121" title="">Characteristics of included studies</a>, <a href="./references#CD007498-sec-0122" title="">Characteristics of excluded studies</a>, and <a href="./references#CD007498-sec-0123" title="">Characteristics of ongoing studies</a> tables. </p> <section id="CD007498-sec-0062"> <h4 class="title">Results of the search</h4> <p>After removal of duplicates, we identified 998 records that we further assessed based on title and abstracts, excluding 919 records. We obtained 79 full‐text study reports, and following assessment excluded 39 that did not meet our inclusion criteria. Eight studies were ongoing trials. From 32 eligible RCTs (9909 participants) including 18 new trials for this 2017 update, we obtained individual participant data from 26 trials including 6708 participants, which were included in the main individual participant data meta‐analysis (see <a href="#CD007498-fig-0001">Figure 1</a>). We did not obtain individual participant data for four trials, and two trials did not include participants with confirmed ARIs. The sensitivity aggregate analysis includes all 32 trials. </p> <div class="figure" id="CD007498-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram.Abbreviations: ARI: acute respiratory infection; IPD: individual participant data; RCT: randomised controlled trial" data-id="CD007498-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> <p>Abbreviations: ARI: acute respiratory infection; IPD: individual participant data; RCT: randomised controlled trial </p> </div> </div> </div> </section> <section id="CD007498-sec-0063"> <h4 class="title">Included studies</h4> <p>We included a total of 26 studies involving 6708 participants in the main individual participant data meta‐analysis. Study characteristics are presented in <a href="#CD007498-tbl-0002">Table 1</a>. </p> <div class="table" id="CD007498-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included trials</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting, type of trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical diagnosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of PCTalgorithm and PCTcut‐offs used (µg/L)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N: ARI participants (study total)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary endpoint</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up time</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reasons for exclusion of patients</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0001" title="AnnaneD , MaximeV , FallerJP , MezherC , Clec'hC , MartelP , et al. Procalcitonin levels to guide antibiotic therapy in adults with non‐microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open2013;3(2):pii: e002186. ">Annane 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe sepsis without overt source of infection and negative blood culture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.5 (&lt; 0.25); R for AB: &gt; 0.5 (&gt; 5.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (62)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants on AB on day 5 post randomisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital stay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 non‐ARI patients (4 of them with post randomisation consent withdrawal)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0002" title="BloosF , TripsE , NierhausA , BriegelJ , HeylandDK , JaschinskiU , et al. Effect of sodium selenite administration and procalcitonin‐guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Internal Medicine2016;176(9):1266‐76. ">Bloos 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe sepsis or septic shock</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinuation at day 4, 7, and 10; R against AB: &lt; 1.0 or &gt; 50% drop to previous value </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219 (1180)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28‐day mortality</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 post randomisation exclusions (informed consent not obtainable), 870 not ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0003" title="BouadmaL , LuytCE , TubachF , CraccoC , AlvarezA , SchwebelC , et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet2010;375(9713):463‐74. ">Bouadma 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suspected bacterial infections during ICU stay without prior AB (&gt; 24 h)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.5 (&lt; 0.25); R for AB: &gt; 0.5 (&gt; 1.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>394 (630)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 post randomisation exclusions (8 withdrew consent, 1 randomised twice); 227 non‐ARI patients </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0004" title="BrancheAR , WalshEE , VargasR , HulbertB , FormicaMA , BaranA , et al. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. Journal of Infectious Diseases2015;212(11):1692‐700. ">Branche 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, medical ward, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower ARI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25 (&gt; 0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265 (300)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic exposure and safety</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0005" title="BrielM , SchuetzP , MuellerB , YoungJ , SchildU , NusbaumerC , et al. Procalcitonin‐guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Archives of Internal Medicine2008;168(18):2000‐7. ">Briel 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary care, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Upper and lower ARI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25 (&gt; 0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458 (458)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days with restricted activities</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No exclusions</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0006" title="BurkhardtO , EwigS , HaagenU , GiersdorfS , HartmannO , WegscheiderK , et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. European Respiratory Journal2010;36(3):601‐7. ">Burkhardt 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary care, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Upper and lower ARI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation; R against AB: &lt; 0.25; R for AB: &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550 (571)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days with restricted activities</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 post randomisation exclusions (2 withdrew consent, 1 due to loss of sample, 15 with autoimmune, inflammatory, or systemic disease, 2 with advanced liver disease, 1 with prior use of antibiotics) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0007" title="Christ‐CrainM , Jaccard‐StolzD , BingisserR , GencayM , HuberP , TammM , et al. Effect of procalcitonin‐guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster‐randomised, single‐blinded intervention trial. Lancet2004;1363(9409):600‐7. ">Christ‐Crain 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower ARI with X‐ray confirmation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25 (&gt; 0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219 (243)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0008" title="Christ‐CrainM , StolzD , BingisserR , MullerC , MiedingerD , HuberPR , et al. Procalcitonin guidance of antibiotic therapy in community‐acquired pneumonia: a randomized trial. American Journal of Respiratory and Critical Care Medicine2006;174(1):84‐93. ">Christ‐Crain 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, medical ward, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAP with X‐ray confirmation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25 (&gt; 0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286 (302)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0009" title="CortiC , FallyM , Fabricius‐BjerreA , MortensenK , JensenBN , AndreassenHF , et al. Point‐of‐care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. International Journal of Chronic Obstructructive Pulmonary Disease2016;11:1381‐9. [DOI: 10.2147/COPD.S104051] ">Corti 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Denmark</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AECOPD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB &lt; 0.25 (0.15)/80% decrease; R for AB &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 (120)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No exclusions</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0010" title="DeJongE , vanOersJA , BeishuizenA , VosP , VermeijdenWJ , HaasLE , et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open‐label trial. Lancet Infectious Diseases2016;16(7):819‐27. ">De Jong 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Netherlands</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critically ill patients with presumed infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 0.5 or &gt; 80% drop</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>994 (1575)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 post randomisation exclusions (25 protocol violations, 4 withdrew informed consent), 552 non‐ARI patients </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0011" title="DeliberatoRO , MarraAR , SanchesPR , MartinoMD , FerreiraCE , PasternakJ , et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagnostic Microbiology and Infectious Disease2013;76(3):266‐71. ">Deliberato 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Septic patients with proven bacterial infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 0.5 or &gt; 90% drop</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU discharge or 14 days' post randomisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0012" title="DingJ , ChenZ , FengK . Procalcitonin‐guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. International Journal of Medical Sciences2013;10(7):903‐7. ">Ding 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute exacerbation of pulmonary fibrosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25; R for AB: &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 post randomisation exclusions (7 lost to follow‐up, 3 withdrew informed consent), 68 data not shared </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0013" title="HochreiterM , KohlerT , SchweigerAM , KeckFS , BeinB , vonSpiegelT , et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care2009;13(3):R83. ">Hochreiter 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suspected bacterial infections and &gt; 1 SIRS criteria</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 1 or &gt; 65% drop over 3 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (110)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital stay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0014" title="KristoffersenKB , SogaardOS , WejseC , BlackFT , GreveT , TarpB , et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission ‐ a randomized trial. Clinical Microbiology and Infection2009;15(5):481‐7. ">Kristoffersen 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Denmark</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, medical ward, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower ARI without X‐ray confirmation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25; R for AB: &gt; 0.25 (&gt; 0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210 (223)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital stay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 post randomisation exclusions (3 no PCT testing, 6 not meeting inclusion criteria, 4 withdrew informed consent) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0015" title="LayiosN , LambermontB , CanivetJL , MorimontP , PreiserJC , GarwegC , et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Critical Care Medicine2012;40(8):2304‐9. ">Layios 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Belgium</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suspected infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation; R against AB: &lt; 0.5 (&lt; 0.25); R for AB: &gt; 0.5 (&gt; 1.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 (509)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 no PCT measurements, 10 missing data, 219 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0016" title="LimaSS , NobreV , deCastro RomanelliRM , ClementeWT , daSilva BittencourtHN , MeloAC , et al. Procalcitonin‐guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Annals of Hematology2016;95(7):1169‐76. ">Lima 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, medical ward, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Febrile neutropenia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 0.5 for 2 days or &gt; 90% drop than highest measured concentration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (62)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 post randomisation exclusion (withdrew informed consent), 62 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0017" title="LongW , DengXQ , TangJG , XieJ , ZhangYC , ZhangY , et al. Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community acquired pneumonia. Zhonghua Nei Ke Za Zhi2009;48(3):216‐9. ">Long 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, outpatients, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAP with X‐ray confirmation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25; R for AB: &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (149)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 post randomisation exclusions due to withdrawal of consent</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0018" title="LongW , DengX , ZhangY , LuG , XieJ , TangJ . Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community acquired pneumonia. Respirology2011;76(1):266‐9. ">Long 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, outpatients, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAP with X‐ray confirmation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25; R for AB: &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 (172)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 post randomisation exclusions (6 lost to follow‐up, 7 withdrew consent, 3 with final diagnosis other than CAP) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0019" title="LongW , LiLJ , HuangGZ , ZhangXM , ZhangYC , TangJG , et al. Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12‐month follow‐up. Critical Care2014;18(5):471. ">Long 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe acute exacerbation of asthma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (180)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No exclusions</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0020" title="Maravić‐StojkovićV , Laušević‐VukL , JovićM , RankovićA , BorzanovićM , MarinkovićJ . Procalcitonin‐based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: a randomized controlled trial. Srpski Arhiv Celokupno Lekarstvo2011;139(11‐12):736‐42. ">Maravić‐Stojković 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serbia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU surgical, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infection after open heart surgery</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation; R for AB: &gt; 0.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (205)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use, AB cost</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital stay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0021" title="NajafiA , KhodadadianA , SanatkarM , Shariat MoharariR , EtezadiF , AhmadiA , et al. The comparison of procalcitonin guidance administer antibiotics with empiric antibiotic therapy in critically ill patients admitted in intensive care unit. Acta Medica Iranica2015;53(9):562‐7. ">Najafi 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SIRS without apparent source of infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation; R for AB: &gt; 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (60)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital stay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 patient data not shared</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0022" title="NobreV , HarbarthS , GrafJD , RohnerP , PuginJ . Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. American Journal of Respiratory and Critical Care Medicine2009;177(5):498‐505. ">Nobre 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suspected severe sepsis or septic shock</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 0.5 (&lt; 0.25) or &gt; 80% drop; R for AB: &gt; 0.5 (&gt; 1.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 (79)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0023" title="OgasawaraT , UmezawaH , NaitoY , TakeuchiT , KatoS , YanoT , et al. Procalcitonin‐guided antibiotic therapy in aspiration pneumonia and an assessment of the continuation of oral intake. Respiratory Investigation2014;52(2):107‐13. ">Ogasawara 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medical ward, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aspiration pneumonia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Predefined duration; AB for 3 d: &lt; 0.5; AB for 5 d: 0.5 to 1.0; AB for 7 d: &gt; 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (105)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse and 30‐day mortality</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 post randomisation exclusions (2 withdrew consent, 7 others), 96 data not shared</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0024" title="OliveiraCF , BotoniFA , OliveiraCR , SilvaCB , PereiraHA , SerufoJC , et al. Procalcitonin versus C‐reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Critical Care Medicine2013;41(10):2336‐43. ">Oliveira 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe sepsis or septic shock</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinuation; initial &lt; 1.0: R against AB: 0.1 at day 4; initial &gt; 1.0: R against: &gt; 90% drop </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days or hospital discharge</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 post randomisation exclusions (2 withdrew consent, 1 technical problems), 36 patients with a final diagnosis other than ARI </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0025" title="SchroederS , HochreiterM , KoehlerT , SchweigerAM , BeinB , KeckFS , et al. Procalcitonin (PCT)‐guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Archives of Surgery2009;394(2):221‐6. ">Schroeder 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe sepsis following abdominal surgery</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 1 or &gt; 65% drop over 3 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital stay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0026" title="SchuetzP , Christ‐CrainM , ThomannR , FalconnierC , WolbersM , WidmerI , et al. Effect of procalcitonin‐based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA2009;302(10):1059‐66. ">Schuetz 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, medical ward, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower ARI with X‐ray confirmation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25 (&gt; 0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1304 (1381)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 post randomisation exclusions due to withdrawal of consent, 55 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0027" title="ShehabiY , SterbaM , GarrettPM , RachakondaKS , StephensD , HarriganP , et al. ProGUARD Study Investigators, ANZICS Clinical Trials Group. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2014;190(10):1102‐10. ">Shehabi 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suspected sepsis, undifferentiated infections</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 0.25 (&lt; 0.1) or &gt; 90% drop</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 (400)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 post randomisation exclusions (6 withdrew consent), 238 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0028" title="StolzD , Christ‐CrainM , BingisserR , LeuppiJ , MiedingerD , MullerC , et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin‐guidance with standard therapy. Chest2007;131(1):9‐19. ">Stolz 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, medical ward, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbated COPD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25 (&gt; 0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208 (226)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to 3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 post randomisation exclusions (absence of COPD)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0029" title="StolzD , SmyrniosN , EggimannP , ParggerH , ThakkarN , SiegemundM , et al. Procalcitonin for reduced antibiotic exposure in ventilator‐associated pneumonia: a randomised study. European Respiratory Journal2009;34(6):1364‐75. ">Stolz 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland, USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAP when intubated &gt; 48 h</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 0.5 (&lt; 0.25) or &gt; 80% drop; R for AB: &gt; 0.5 (&gt; 1.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 (101)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB‐free days alive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No exclusions</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0030" title="TangJ , LongW , YanL , ZhangY , XieJ , LuG , et al. Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial. BMC Infectious Diseases2013;13:596. [DOI: 10.1186/1471‐2334‐13‐596] ">Tang 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation of asthma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (265)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 post randomisation exclusions (5 lost to follow‐up, 3 died, 2 withdrew consent), 255 data not shared </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0031" title="VerduriA , LuppiF , D'AmicoR , BalduzziS , ViciniR , LiveraniA , et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS ONE2015;10(3):e0118241. ">Verduri 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, medical ward, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AECOPD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation; R against AB:&lt; 0.1; R for AB: &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178 (183)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of exacerbations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 post randomisation exclusions (5 lost to follow‐up because they did not meet the inclusion criteria) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0032" title="WangJX , ZhangSM , LiXH , ZhangY , XuZY , CaoB . Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. International Journal of Infectious Diseases2016;48:40‐5. [DOI: 10.1016/j.ijid.2016.04.024] ">Wang 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AECOPD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants had initial PCT &lt; 0.1; AB group treated with AB for at least 3 days, control group no AB in the first 10 days </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191 (194)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment success within 10 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 post randomisation exclusions (3 with pneumonia according to CT scan)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AB: antibiotic<br/> AECOPD: acute exacerbation of chronic obstructive pulmonary disease<br/> ARI: acute respiratory infection<br/> CAP: community‐acquired pneumonia<br/> COPD: chronic obstructive pulmonary disease<br/> CT: computed tomography<br/> d: days<br/> ED: emergency department<br/> h: hours<br/> ICU: intensive care unit<br/> PCT: procalcitonin<br/> R: recommendation for or against antibiotics<br/> SIRS: systemic inflammatory response syndrome<br/> VAP: ventilator‐associated pneumonia </p> </div> </div> <section id="CD007498-sec-0064"> <h5 class="title">Participants</h5> <p>Baseline characteristics of included participants were similar in the PCT and control groups with respect to important prognostic features (<a href="#CD007498-tbl-0003">Table 2</a>). Most participants were recruited either in the emergency department or ICU setting, and CAP was the most frequent ARI diagnosis, reported in more than 40% of participants. </p> <div class="table" id="CD007498-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of included participants</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parameter</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control (n = 3372)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PCT group (n = 3336)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Demographics</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age (year), mean (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.2 ± 18.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.7 ± 18.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male gender, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1910 (56.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1898 (56.9%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Clinical setting, no (%)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary care</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>501 (14.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (15.2%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Emergency department</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1638 (48.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1615 (48.4%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intensive care unit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1233 (36.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1214 (36.4%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Primary diagnosis</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total upper ARI, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280 (8.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>292 (8.8%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common cold</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 (4.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149 (4.5%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rhino‐sinusitis, otitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (2.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (2.2%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharyngitis, tonsillitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (1.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 (1.8%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total lower ARI, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3092 (91.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3044 (91.2%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐acquired pneumonia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1468 (43.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1442 (43.2%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐acquired pneumonia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 (7.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243 (7.3%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ventilator‐associated pneumonia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186 (5.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 (5.8%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute bronchitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287 (8.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257 (7.7%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation of COPD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>631 (18.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621 (18.6%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation of asthma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (3.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 (4.3%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other lower ARI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 (3.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144 (4.3%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Procalcitonin upon enrolment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCT&lt; 0.1 ug/L</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>921 (35.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>981 (30.9%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCT 0.1 to 0.25 ug/L</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521 (20.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>608 (19.2%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCT &gt; 0.25 to 0.5 ug/L</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>308 (11.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>383 (12.1%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCT &gt; 0.5 to 2.0 ug/L</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>358 (13.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>520 (16.4%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCT &gt; 2.0 ug/L</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>482 (18.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>679 (21.4%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ARI: acute respiratory infection<br/> COPD: chronic obstructive pulmonary disease<br/> PCT: procalcitonin<br/> SD: standard deviation </p> </div> </div> </section> <section id="CD007498-sec-0065"> <h5 class="title">Settings</h5> <p>Trials were conducted in 12 countries: Switzerland, Germany, France, Italy, USA, China, Denmark, Netherlands, Brazil, Belgium, Australia, and Serbia. Trials were conducted in different clinical settings including primary care, emergency departments and medical wards, and ICU. There were two primary care trials with upper and lower respiratory infection patients; 11 emergency department and medical ward trials with lower ARI patients; and 13 ICU trials with mostly septic patients due to infections of the lower respiratory tract. </p> </section> <section id="CD007498-sec-0066"> <h5 class="title">Interventions</h5> <p>Procalcitonin algorithms used in the different trials were similar in concept and recommended initiation and/or continuation of antibiotic therapy based on similar PCT cut‐off levels (reviewed in <a href="./references#CD007498-bbs2-0088" title="SchuetzP , ChiappaV , BrielM , GreenwaldJL . Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine2011;171(15):1322‐31. ">Schuetz 2011a</a>). However, there were differences: some trials in primary care and the emergency department used only a single PCT measurement on admission to guide initiation of antibiotics, while the other trials (predominantly in hospitalised patients with severe infections) used repeated measurements for guiding the duration of treatment. One trial used a point‐of‐care device (<a href="./references#CD007498-bbs2-0009" title="CortiC , FallyM , Fabricius‐BjerreA , MortensenK , JensenBN , AndreassenHF , et al. Point‐of‐care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. International Journal of Chronic Obstructructive Pulmonary Disease2016;11:1381‐9. [DOI: 10.2147/COPD.S104051] ">Corti 2016</a>). Adherence to algorithms varied, ranging from 44% to 100% (<a href="#CD007498-tbl-0004">Table 3</a>). </p> <div class="table" id="CD007498-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Quality assessment of trials</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Allocation concealment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Blinded<br/> outcome assessment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up for mortality</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adherence to PCT algorithm in PCT group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up for mortality</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0001" title="AnnaneD , MaximeV , FallerJP , MezherC , Clec'hC , MartelP , et al. Procalcitonin levels to guide antibiotic therapy in adults with non‐microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open2013;3(2):pii: e002186. ">Annane 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58/58 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0002" title="BloosF , TripsE , NierhausA , BriegelJ , HeylandDK , JaschinskiU , et al. Effect of sodium selenite administration and procalcitonin‐guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Internal Medicine2016;176(9):1266‐76. ">Bloos 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1045/1089 (96%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.6% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days and 90 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0003" title="BouadmaL , LuytCE , TubachF , CraccoC , AlvarezA , SchwebelC , et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet2010;375(9713):463‐74. ">Bouadma 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>393/394 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days and 60 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0004" title="BrancheAR , WalshEE , VargasR , HulbertB , FormicaMA , BaranA , et al. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. Journal of Infectious Diseases2015;212(11):1692‐700. ">Branche 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation using blocks of 4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250/300 (83.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month and 3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0005" title="BrielM , SchuetzP , MuellerB , YoungJ , SchildU , NusbaumerC , et al. Procalcitonin‐guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Archives of Internal Medicine2008;168(18):2000‐7. ">Briel 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>454/458 (99%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0006" title="BurkhardtO , EwigS , HaagenU , GiersdorfS , HartmannO , WegscheiderK , et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. European Respiratory Journal2010;36(3):601‐7. ">Burkhardt 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>546/550 (99%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0007" title="Christ‐CrainM , Jaccard‐StolzD , BingisserR , GencayM , HuberP , TammM , et al. Effect of procalcitonin‐guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster‐randomised, single‐blinded intervention trial. Lancet2004;1363(9409):600‐7. ">Christ‐Crain 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No (alternating weeks)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230/243 (95%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 to 14 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0008" title="Christ‐CrainM , StolzD , BingisserR , MullerC , MiedingerD , HuberPR , et al. Procalcitonin guidance of antibiotic therapy in community‐acquired pneumonia: a randomized trial. American Journal of Respiratory and Critical Care Medicine2006;174(1):84‐93. ">Christ‐Crain 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (sequentially numbered, opaque, sealed envelopes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300/302 (99%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0009" title="CortiC , FallyM , Fabricius‐BjerreA , MortensenK , JensenBN , AndreassenHF , et al. Point‐of‐care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. International Journal of Chronic Obstructructive Pulmonary Disease2016;11:1381‐9. [DOI: 10.2147/COPD.S104051] ">Corti 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (randomisation algorithm was concealed to treating clinicians and participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120/120 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.1% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0010" title="DeJongE , vanOersJA , BeishuizenA , VosP , VermeijdenWJ , HaasLE , et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open‐label trial. Lancet Infectious Diseases2016;16(7):819‐27. ">De Jong 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1546/1546 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days and 1 year</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0011" title="DeliberatoRO , MarraAR , SanchesPR , MartinoMD , FerreiraCE , PasternakJ , et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagnostic Microbiology and Infectious Disease2013;76(3):266‐71. ">Deliberato 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (opaque, sealed envelopes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81/81 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0012" title="DingJ , ChenZ , FengK . Procalcitonin‐guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. International Journal of Medical Sciences2013;10(7):903‐7. ">Ding 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68/78 (87.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0013" title="HochreiterM , KohlerT , SchweigerAM , KeckFS , BeinB , vonSpiegelT , et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care2009;13(3):R83. ">Hochreiter 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No (unconcealed drawing of lots)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43/43 (100% until discharge)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0014" title="KristoffersenKB , SogaardOS , WejseC , BlackFT , GreveT , TarpB , et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission ‐ a randomized trial. Clinical Microbiology and Infection2009;15(5):481‐7. ">Kristoffersen 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210/210 (100% until discharge)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0015" title="LayiosN , LambermontB , CanivetJL , MorimontP , PreiserJC , GarwegC , et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Critical Care Medicine2012;40(8):2304‐9. ">Layios 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>509/509 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intensive care unit LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0016" title="LimaSS , NobreV , deCastro RomanelliRM , ClementeWT , daSilva BittencourtHN , MeloAC , et al. Procalcitonin‐guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Annals of Hematology2016;95(7):1169‐76. ">Lima 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (sequentially numbered, opaque, sealed envelopes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61/62 (98.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.3% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days and 90 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0017" title="LongW , DengXQ , TangJG , XieJ , ZhangYC , ZhangY , et al. Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community acquired pneumonia. Zhonghua Nei Ke Za Zhi2009;48(3):216‐9. ">Long 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No (odd and even patient ID numbers)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127/127 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0018" title="LongW , DengX , ZhangY , LuG , XieJ , TangJ . Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community acquired pneumonia. Respirology2011;76(1):266‐9. ">Long 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No (odd and even patient ID numbers)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156/156 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0019" title="LongW , LiLJ , HuangGZ , ZhangXM , ZhangYC , TangJG , et al. Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12‐month follow‐up. Critical Care2014;18(5):471. ">Long 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169/180 (93.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.6% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS and 1 year</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0020" title="Maravić‐StojkovićV , Laušević‐VukL , JovićM , RankovićA , BorzanovićM , MarinkovićJ . Procalcitonin‐based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: a randomized controlled trial. Srpski Arhiv Celokupno Lekarstvo2011;139(11‐12):736‐42. ">Maravić‐Stojković 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205/205 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days and LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0021" title="NajafiA , KhodadadianA , SanatkarM , Shariat MoharariR , EtezadiF , AhmadiA , et al. The comparison of procalcitonin guidance administer antibiotics with empiric antibiotic therapy in critically ill patients admitted in intensive care unit. Acta Medica Iranica2015;53(9):562‐7. ">Najafi 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/30 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0022" title="NobreV , HarbarthS , GrafJD , RohnerP , PuginJ . Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. American Journal of Respiratory and Critical Care Medicine2009;177(5):498‐505. ">Nobre 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (sequentially numbered, opaque, sealed envelopes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52/52 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days and LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0023" title="OgasawaraT , UmezawaH , NaitoY , TakeuchiT , KatoS , YanoT , et al. Procalcitonin‐guided antibiotic therapy in aspiration pneumonia and an assessment of the continuation of oral intake. Respiratory Investigation2014;52(2):107‐13. ">Ogasawara 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96/96 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0024" title="OliveiraCF , BotoniFA , OliveiraCR , SilvaCB , PereiraHA , SerufoJC , et al. Procalcitonin versus C‐reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Critical Care Medicine2013;41(10):2336‐43. ">Oliveira 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94/94 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.2% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0025" title="SchroederS , HochreiterM , KoehlerT , SchweigerAM , BeinB , KeckFS , et al. Procalcitonin (PCT)‐guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Archives of Surgery2009;394(2):221‐6. ">Schroeder 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No (unconcealed drawing of lots)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/8 (100% until discharge)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0026" title="SchuetzP , Christ‐CrainM , ThomannR , FalconnierC , WolbersM , WidmerI , et al. Effect of procalcitonin‐based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA2009;302(10):1059‐66. ">Schuetz 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1358/1359 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0027" title="ShehabiY , SterbaM , GarrettPM , RachakondaKS , StephensD , HarriganP , et al. ProGUARD Study Investigators, ANZICS Clinical Trials Group. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2014;190(10):1102‐10. ">Shehabi 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>394/394 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS and 90 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0028" title="StolzD , Christ‐CrainM , BingisserR , LeuppiJ , MiedingerD , MullerC , et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin‐guidance with standard therapy. Chest2007;131(1):9‐19. ">Stolz 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (sequentially numbered, opaque, sealed envelopes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208/208 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0029" title="StolzD , SmyrniosN , EggimannP , ParggerH , ThakkarN , SiegemundM , et al. Procalcitonin for reduced antibiotic exposure in ventilator‐associated pneumonia: a randomised study. European Respiratory Journal2009;34(6):1364‐75. ">Stolz 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (sequentially numbered, opaque, sealed envelopes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101/101 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0030" title="TangJ , LongW , YanL , ZhangY , XieJ , LuG , et al. Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial. BMC Infectious Diseases2013;13:596. [DOI: 10.1186/1471‐2334‐13‐596] ">Tang 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (sequentially numbered, opaque, sealed envelopes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258/265 (97.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0031" title="VerduriA , LuppiF , D'AmicoR , BalduzziS , ViciniR , LiveraniA , et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS ONE2015;10(3):e0118241. ">Verduri 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178/178 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0032" title="WangJX , ZhangSM , LiXH , ZhangY , XuZY , CaoB . Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. International Journal of Infectious Diseases2016;48:40‐5. [DOI: 10.1016/j.ijid.2016.04.024] ">Wang 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (those responsible for allocation concealment were not involved in the measurement of results) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191/191 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.3% adherence (17 participants in the control group received AB)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LOS: length of stay<br/> PCT: procalcitonin </p> </div> </div> </section> <section id="CD007498-sec-0067"> <h5 class="title">Comparators</h5> <p>In control group participants, PCT was not used to guide treatment decisions, but this decision was up to the treating physician team. In some trials, physicians were asked to follow antibiotic guidelines for control group participants (<a href="./references#CD007498-bbs2-0005" title="BrielM , SchuetzP , MuellerB , YoungJ , SchildU , NusbaumerC , et al. Procalcitonin‐guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Archives of Internal Medicine2008;168(18):2000‐7. ">Briel 2008</a>; <a href="./references#CD007498-bbs2-0026" title="SchuetzP , Christ‐CrainM , ThomannR , FalconnierC , WolbersM , WidmerI , et al. Effect of procalcitonin‐based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA2009;302(10):1059‐66. ">Schuetz 2009</a>). In one trial, the control group was guided with C‐reactive protein levels (<a href="./references#CD007498-bbs2-0024" title="OliveiraCF , BotoniFA , OliveiraCR , SilvaCB , PereiraHA , SerufoJC , et al. Procalcitonin versus C‐reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Critical Care Medicine2013;41(10):2336‐43. ">Oliveira 2013</a>). </p> </section> <section id="CD007498-sec-0068"> <h5 class="title">Funding sources</h5> <p>All studies were investigator‐initiated trials. Half of the trials were funded by national agencies or did not report funding; the other half of the trials received funding from the biomarker industry (e.g. Thermo Fisher Scientific). </p> </section> </section> <section id="CD007498-sec-0069"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 39 studies due to wrong intervention (n = 1), wrong population (n = 2), and wrong design (not RCT) (n = 36). A total of nine studies reported as ongoing in the 2012 review were now available for assessment; we included four of these studies in this current update (<a href="./references#CD007498-bbs2-0001" title="AnnaneD , MaximeV , FallerJP , MezherC , Clec'hC , MartelP , et al. Procalcitonin levels to guide antibiotic therapy in adults with non‐microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open2013;3(2):pii: e002186. ">Annane 2013</a>; <a href="./references#CD007498-bbs2-0002" title="BloosF , TripsE , NierhausA , BriegelJ , HeylandDK , JaschinskiU , et al. Effect of sodium selenite administration and procalcitonin‐guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Internal Medicine2016;176(9):1266‐76. ">Bloos 2016</a>; <a href="./references#CD007498-bbs2-0010" title="DeJongE , vanOersJA , BeishuizenA , VosP , VermeijdenWJ , HaasLE , et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open‐label trial. Lancet Infectious Diseases2016;16(7):819‐27. ">De Jong 2016</a>; <a href="./references#CD007498-bbs2-0016" title="LimaSS , NobreV , deCastro RomanelliRM , ClementeWT , daSilva BittencourtHN , MeloAC , et al. Procalcitonin‐guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Annals of Hematology2016;95(7):1169‐76. ">Lima 2016</a>), and did not include five studies due to wrong population (paediatrics). </p> <section id="CD007498-sec-0070"> <h5 class="title">Ongoing studies</h5> <p>Our searches of the trial register identified seven ongoing studies that we will assess for inclusion for the next review update (<a href="./references#CD007498-bbs1-0003" title="">Ongoing studies</a>). These studies focus on the utility of PCT in people with pneumonitis (<a href="./references#CD007498-bbs2-0055" title="NCT02862314 . PROcalcitonin Pneumonia/Pneumonitis Associated With ASPIration (PROPASPI). clinicaltrials.gov/ct2/show/NCT02862314 First received: July 29, 2016. ">NCT02862314</a>), pulmonary embolism (<a href="./references#CD007498-bbs2-0051" title="NCT02261610 . Pulmonary Embolism and PCT. PE‐PCT Study. clinicaltrials.gov/ct2/show/NCT02261610 First received: September 5, 2014. ">NCT02261610</a>), lower respiratory infection (<a href="./references#CD007498-bbs2-0050" title="NCT02130986 . Procalcitonin Antibiotic Consensus Trial (ProACT). clinicaltrials.gov/ct2/show/study/NCT02130986 First received: May 1, 2014. ">NCT02130986</a>), heart failure (<a href="./references#CD007498-bbs2-0054" title="NCT02787603 . Procalcitonin in Early Antibiotic Interruption in Patient With Bacterial Pulmonary infeCtion and Acute Heart Failure (EPICAD). clinicaltrials.gov/ct2/show/NCT02787603 First received: May 25, 2016. ">NCT02787603</a>), and intraoperative positive‐end expiratory pressure optimisation (<a href="./references#CD007498-bbs2-0056" title="NCT02931409 . Intraoperative PEEP optimization: effects on postoperative pulmonary complications and inflammatory response. clinicaltrials.gov/ct2/show/NCT02931409 First received: October 5, 2016. ">NCT02931409</a>). Two trials are antibiotic efficacy trials (<a href="./references#CD007498-bbs2-0052" title="NCT02332577 . Study to compare the efficacy of pristinamycin (Pyostacine) versus amoxicillin in the treatment of acute community acquired pneumonia. clinicaltrials.gov/ct2/show/NCT02332577 First received: January 5, 2015. ">NCT02332577</a>; <a href="./references#CD007498-bbs2-0053" title="NCT02440828 . Addition of tobramycin inhalation in the treatment of ventilator associated pneumonia (VAPORISE). clinicaltrials.gov/ct2/show/NCT02440828 First received: March 13, 2015. ">NCT02440828</a>). </p> </section> </section> </section> <section id="CD007498-sec-0071"> <h3 class="title">Risk of bias in included studies</h3> <p>The overall risk of bias is presented graphically in <a href="#CD007498-fig-0002">Figure 2</a> and <a href="#CD007498-fig-0003">Figure 3</a>. The risk of bias was mostly low for random sequence generation, allocation concealment, incomplete outcome data, and selective reporting; unclear for blinding of personnel in all studies; and mostly high for blinding of outcome assessment. </p> <div class="figure" id="CD007498-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007498-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD007498-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007498-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD007498-sec-0072"> <h4 class="title">Allocation</h4> <p>All studies randomised participants to intervention (PCT testing) or control groups. A total of 25 trials with mainly computer‐generated lists and centralised randomisation were at low risk of selection bias. Seven trials were at high or unclear risk of selection bias. Risk for selection bias with regard to random sequence generation was due to weekly allocation (<a href="./references#CD007498-bbs2-0007" title="Christ‐CrainM , Jaccard‐StolzD , BingisserR , GencayM , HuberP , TammM , et al. Effect of procalcitonin‐guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster‐randomised, single‐blinded intervention trial. Lancet2004;1363(9409):600‐7. ">Christ‐Crain 2004</a>), unnumbered envelopes (<a href="./references#CD007498-bbs2-0008" title="Christ‐CrainM , StolzD , BingisserR , MullerC , MiedingerD , HuberPR , et al. Procalcitonin guidance of antibiotic therapy in community‐acquired pneumonia: a randomized trial. American Journal of Respiratory and Critical Care Medicine2006;174(1):84‐93. ">Christ‐Crain 2006</a>; <a href="./references#CD007498-bbs2-0028" title="StolzD , Christ‐CrainM , BingisserR , LeuppiJ , MiedingerD , MullerC , et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin‐guidance with standard therapy. Chest2007;131(1):9‐19. ">Stolz 2007</a>), use of odd and even patient identification numbers (<a href="./references#CD007498-bbs2-0017" title="LongW , DengXQ , TangJG , XieJ , ZhangYC , ZhangY , et al. Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community acquired pneumonia. Zhonghua Nei Ke Za Zhi2009;48(3):216‐9. ">Long 2009</a>; <a href="./references#CD007498-bbs2-0018" title="LongW , DengX , ZhangY , LuG , XieJ , TangJ . Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community acquired pneumonia. Respirology2011;76(1):266‐9. ">Long 2011</a>), and unconcealed drawing of lots (<a href="./references#CD007498-bbs2-0013" title="HochreiterM , KohlerT , SchweigerAM , KeckFS , BeinB , vonSpiegelT , et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care2009;13(3):R83. ">Hochreiter 2009</a>; <a href="./references#CD007498-bbs2-0025" title="SchroederS , HochreiterM , KoehlerT , SchweigerAM , BeinB , KeckFS , et al. Procalcitonin (PCT)‐guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Archives of Surgery2009;394(2):221‐6. ">Schroeder 2009</a>). </p> </section> <section id="CD007498-sec-0073"> <h4 class="title">Blinding</h4> <p>None of the included trials blinded physicians to group allocation because PCT was used for decision making in the intervention group, thus all trials had unclear risk for blinding of participants and personnel. </p> <p>All trials used blinded outcome assessment (<a href="./references#CD007498-bbs2-0005" title="BrielM , SchuetzP , MuellerB , YoungJ , SchildU , NusbaumerC , et al. Procalcitonin‐guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Archives of Internal Medicine2008;168(18):2000‐7. ">Briel 2008</a>; <a href="./references#CD007498-bbs2-0003" title="BouadmaL , LuytCE , TubachF , CraccoC , AlvarezA , SchwebelC , et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet2010;375(9713):463‐74. ">Bouadma 2010</a>; <a href="./references#CD007498-bbs2-0004" title="BrancheAR , WalshEE , VargasR , HulbertB , FormicaMA , BaranA , et al. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. Journal of Infectious Diseases2015;212(11):1692‐700. ">Branche 2015</a>; <a href="./references#CD007498-bbs2-0015" title="LayiosN , LambermontB , CanivetJL , MorimontP , PreiserJC , GarwegC , et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Critical Care Medicine2012;40(8):2304‐9. ">Layios 2012</a>; <a href="./references#CD007498-bbs2-0026" title="SchuetzP , Christ‐CrainM , ThomannR , FalconnierC , WolbersM , WidmerI , et al. Effect of procalcitonin‐based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA2009;302(10):1059‐66. ">Schuetz 2009</a>; <a href="./references#CD007498-bbs2-0027" title="ShehabiY , SterbaM , GarrettPM , RachakondaKS , StephensD , HarriganP , et al. ProGUARD Study Investigators, ANZICS Clinical Trials Group. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2014;190(10):1102‐10. ">Shehabi 2014</a>; <a href="./references#CD007498-bbs2-0028" title="StolzD , Christ‐CrainM , BingisserR , LeuppiJ , MiedingerD , MullerC , et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin‐guidance with standard therapy. Chest2007;131(1):9‐19. ">Stolz 2007</a>; <a href="./references#CD007498-bbs2-0030" title="TangJ , LongW , YanL , ZhangY , XieJ , LuG , et al. Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial. BMC Infectious Diseases2013;13:596. [DOI: 10.1186/1471‐2334‐13‐596] ">Tang 2013</a>), employing blinded telephone interviews to assess vital status and other outcomes. </p> </section> <section id="CD007498-sec-0074"> <h4 class="title">Incomplete outcome data</h4> <p>The included trials had a high follow‐up for mortality with few participants lost to follow‐up (<a href="#CD007498-tbl-0004">Table 3</a>). In seven trials, outcome assessment was done after hospital or ICU discharge (<a href="./references#CD007498-bbs2-0011" title="DeliberatoRO , MarraAR , SanchesPR , MartinoMD , FerreiraCE , PasternakJ , et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagnostic Microbiology and Infectious Disease2013;76(3):266‐71. ">Deliberato 2013</a>; <a href="./references#CD007498-bbs2-0013" title="HochreiterM , KohlerT , SchweigerAM , KeckFS , BeinB , vonSpiegelT , et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care2009;13(3):R83. ">Hochreiter 2009</a>; <a href="./references#CD007498-bbs2-0014" title="KristoffersenKB , SogaardOS , WejseC , BlackFT , GreveT , TarpB , et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission ‐ a randomized trial. Clinical Microbiology and Infection2009;15(5):481‐7. ">Kristoffersen 2009</a>; <a href="./references#CD007498-bbs2-0015" title="LayiosN , LambermontB , CanivetJL , MorimontP , PreiserJC , GarwegC , et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Critical Care Medicine2012;40(8):2304‐9. ">Layios 2012</a>; <a href="./references#CD007498-bbs2-0017" title="LongW , DengXQ , TangJG , XieJ , ZhangYC , ZhangY , et al. Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community acquired pneumonia. Zhonghua Nei Ke Za Zhi2009;48(3):216‐9. ">Long 2009</a>; <a href="./references#CD007498-bbs2-0025" title="SchroederS , HochreiterM , KoehlerT , SchweigerAM , BeinB , KeckFS , et al. Procalcitonin (PCT)‐guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Archives of Surgery2009;394(2):221‐6. ">Schroeder 2009</a>; <a href="./references#CD007498-bbs2-0027" title="ShehabiY , SterbaM , GarrettPM , RachakondaKS , StephensD , HarriganP , et al. ProGUARD Study Investigators, ANZICS Clinical Trials Group. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2014;190(10):1102‐10. ">Shehabi 2014</a>). One trial had a high number of post randomisation exclusions (six in the intervention arm versus four in the control group) and thus had an unclear risk of bias (<a href="./references#CD007498-bbs2-0012" title="DingJ , ChenZ , FengK . Procalcitonin‐guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. International Journal of Medical Sciences2013;10(7):903‐7. ">Ding 2013</a>). </p> </section> <section id="CD007498-sec-0075"> <h4 class="title">Selective reporting</h4> <p>No reporting bias was found when study protocols and final results were compared. However, we did not find registration numbers for four trials (<a href="./references#CD007498-bbs2-0012" title="DingJ , ChenZ , FengK . Procalcitonin‐guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. International Journal of Medical Sciences2013;10(7):903‐7. ">Ding 2013</a>; <a href="./references#CD007498-bbs2-0015" title="LayiosN , LambermontB , CanivetJL , MorimontP , PreiserJC , GarwegC , et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Critical Care Medicine2012;40(8):2304‐9. ">Layios 2012</a>; <a href="./references#CD007498-bbs2-0020" title="Maravić‐StojkovićV , Laušević‐VukL , JovićM , RankovićA , BorzanovićM , MarinkovićJ . Procalcitonin‐based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: a randomized controlled trial. Srpski Arhiv Celokupno Lekarstvo2011;139(11‐12):736‐42. ">Maravić‐Stojković 2011</a>; <a href="./references#CD007498-bbs2-0021" title="NajafiA , KhodadadianA , SanatkarM , Shariat MoharariR , EtezadiF , AhmadiA , et al. The comparison of procalcitonin guidance administer antibiotics with empiric antibiotic therapy in critically ill patients admitted in intensive care unit. Acta Medica Iranica2015;53(9):562‐7. ">Najafi 2015</a>), which we considered to be at unclear risk of bias. We found no evidence of reporting bias by visual inspection of funnel plots (<a href="#CD007498-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD007498-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, outcome: 1.1 Mortality at 30 days." data-id="CD007498-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, outcome: 1.1 Mortality at 30 days. </p> </div> </div> </div> </section> <section id="CD007498-sec-0076"> <h4 class="title">Other potential sources of bias</h4> <p>Another potential source of bias relates to low adherence to the PCT algorithms, particularly for safety endpoints. Overall, adherence varied, ranging from 44% to 100% (<a href="#CD007498-tbl-0004">Table 3</a>). </p> <p>With regard to funding, 16 trials reported no industry funding (six did not report any funding, 10 reported public funding), and in 16 trials Thermo Fisher, the producer of the PCT assay, funded or co funded the studies by providing free‐of‐charge PCT kits or additional research funds, or both. </p> </section> </section> <section id="CD007498-sec-0077"> <h3 class="title" id="CD007498-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD007498-tbl-0001"><b>Summary of findings for the main comparison</b> Procalcitonin algorithm compared to standard care for guiding antibiotic therapy in acute respiratory tract infections</a> </p> <section id="CD007498-sec-0078"> <h4 class="title">Primary outcomes</h4> <section id="CD007498-sec-0079"> <h5 class="title">1. All‐cause mortality following randomisation up to a follow‐up time of 30 days</h5> <p>There were 286 deaths in 3336 PCT‐guided participants (8.6%) compared to 336 in 3372 controls (10.0%) resulting in a significantly lower mortality associated with PCT‐guided therapy (adjusted odds ratio (OR) 0.83, 95% confidence interval (CI) 0.70 to 0.99, P = 0.037) (<a href="#CD007498-tbl-0005">Table 4</a>). This effect was consistent across clinical settings (P for interaction &gt; 0.05), although mortality could not be estimated in primary care trials because only one death was reported in a control group participant. The effect on mortality was also consistent among different ARI diagnoses (CAP, COPD, bronchitis, VAP) (P for interaction &gt; 0.05). As a further sensitivity analysis and to investigate heterogeneity among trials, we also calculated an aggregate data meta‐analysis based on the aggregate results of all 32 potentially eligible trials (thus not limited to ARI participants only). In this analysis, the results proved robust, although the mortality estimate did not reach statistical significance (OR 0.89, 95% CI 0.78 to 1.01; <a href="./references#CD007498-fig-0007" title="">Analysis 1.1</a>; <a href="#CD007498-fig-0005">Figure 5</a>). There was no evidence of heterogeneity (I<sup>2</sup> = 0%). </p> <div class="figure" id="CD007498-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, outcome: 1.1 Mortality at 30 days." data-id="CD007498-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, outcome: 1.1 Mortality at 30 days. </p> </div> </div> </div> <div class="table" id="CD007498-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Clinical endpoints overall and stratified by setting and ARI diagnosis</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PCT group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of effect: adjusted OR or difference (95% CI), P value</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P for interaction</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3372</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3336</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>336 (10.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286 (8.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.70 to 0.99), P = 0.037</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>841 (24.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>768 (23.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.80 to 1.01), P = 0.068</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of ICU stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3 ± 16.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7 ± 17.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39 (‐0.81 to 1.58), P = 0.524</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7 ± 20.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.4 ± 18.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.19 (‐0.96 to 0.58), P = 0.626</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic‐related side effects, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>336 (22.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247 (16.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.57 to 0.82), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>According to setting</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary care</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>501</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (0.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164 (32.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159 (31.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.73 to 1.25), P = 0.751</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.715</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days with restricted activities, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9 ± 4.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9 ± 4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (‐0.44 to 0.59), P = 0.777</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic‐related side effects, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 (25.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 (20.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.46 to 0.91), P = 0.012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.596</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Emergency department</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1638</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1615</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (3.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (3.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.63 to 1.33), P = 0.635</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.546</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>292 (17.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259 (16.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87 (0.72 to 1.05), P = 0.141</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.807</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 ± 10.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 ± 7.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.14 (‐0.73 to 0.44), P = 0.631</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.684</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic‐related side effects, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208 (20.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145 (14.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.52 to 0.83), P = 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.596</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1233</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1214</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273 (22.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229 (19.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.69 to 1.02), P = 0.081</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.619</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of ICU stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.8 ± 16.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.3 ± 17.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56 (‐0.82 to 1.93), P = 0.427</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.849</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.3 ± 26.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.8 ± 23.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.33 (‐2.28 to 1.62), P = 0.739</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.641</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>According to diagnosis</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Community‐acquired pneumonia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1468</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1442</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206 (14.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175 (12.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.66 to 1.03), P = 0.083</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.958</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385 (26.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317 (22.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (0.66 to 0.93), P = 0.005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.052</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of ICU stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5 ± 10.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.9 ± 13.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.45 (0.15 to 2.75), P = 0.029</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.119</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3 ± 15.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9 ± 16.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74 (‐0.25 to 1.73), P = 0.143</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.094</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic‐related side effects, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186 (27.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (19.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62 (0.48 to 0.80), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.227</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbation of COPD</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>631</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (3.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (3.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 (0.43 to 1.48), P = 0.472</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.847</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (17.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 (16.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.70 to 1.27), P = 0.704</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.676</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.3 ± 13.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4 ± 7.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.60 (‐1.84 to 0.64), P = 0.342</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.658</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic‐related side effects, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (10.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (10.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.53 to 1.63), P = 0.805</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.198</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute bronchitis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (0.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 (19.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 (20.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 (0.72 to 1.70), P = 0.643</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6 ± 5.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 ± 4.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.21 (‐0.90 to 0.48), P = 0.556</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic‐related side effects, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (21.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (17.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (0.49 to 1.22), P = 0.263</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.657</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventilator‐associated pneumonia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (15.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (12.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 (0.41 to 1.39), P = 0.366</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.644</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (27.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (22.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (0.48 to 1.28), P = 0.332</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.522</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of ICU stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.5 ± 20.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.8 ± 19.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.74 (‐5.64 to 2.17), P = 0.383</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.441</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.8 ± 27.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.0 ± 23.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.14 (‐7.04 to 2.75), P = 0.391</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.448</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Measures of effect: dichotomous outcomes are reported as adjusted OR (95% CI) and continuous outcomes are adjusted mean differences and confidence intervals </p> <p>ARI: acute respiratory infection<br/> CI: confidence interval<br/> COPD: chronic obstructive pulmonary disease<br/> ICU: intensive care unit<br/> NA: not applicable<br/> OR: odds ratio<br/> PCT: procalcitonin<br/> SD: standard deviation </p> </div> </div> </section> <section id="CD007498-sec-0080"> <h5 class="title">2. Setting‐specific treatment failure within 30 days of inclusion</h5> <p>Treatment failure was not significantly lower in PCT‐guided participants (23.0% versus 24.9%, adjusted OR 0.90, 95% CI 0.80 to 1.01, P = 0.068). These results were similar among subgroups by clinical setting and type of respiratory infection (P for interaction &gt; 0.05). With an OR of 0.90 (95% CI 0.81 to 0.99), treatment failure was significantly lower in PCT group participants in an aggregate data meta‐analysis based on all 32 potentially eligible trials (thus relying on the original definition of treatment failure as used in the trials). There was no evidence of heterogeneity (I<sup>2</sup> = 0%) (<a href="#CD007498-fig-0006">Figure 6</a>). We also performed several predefined sensitivity analyses, which showed no evidence for interactions (see summary in <a href="#CD007498-tbl-0006">Table 5</a>). </p> <div class="figure" id="CD007498-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, outcome: 1.2 Treatment failure at 30 days." data-id="CD007498-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, outcome: 1.2 Treatment failure at 30 days. </p> </div> </div> </div> <div class="table" id="CD007498-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analysis</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Main analysis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PCT group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adjusted OR (95% CI), P value</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P for interaction</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>336 (10.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>286 (8.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.70 to 0.99), P = 0.037</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Adherence</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82 (4.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 (4.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.63 to 1.22), P = 0.434</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.617</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low adherence (&lt; 70% or not reporting)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254 (16.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>211 (14.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.67 to 1.02), P = 0.073</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Allocation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low risk for allocation concealment bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>305 (10.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 (8.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.67 to 0.97), P = 0.021</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.229</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High risk for allocation concealment bias (or not reporting)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (6.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (7.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.66 to 1.91), P = 0.672</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Blinding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blinded outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113 (6.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102 (5.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.64 to 1.13), P = 0.259</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.537</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No blinded outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>223 (13.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184 (11.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.65 to 1.01), P = 0.062</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Follow up for mortality at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>275 (10.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>224 (8.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.67 to 0.99), P = 0.039</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.325</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Follow up for mortality &lt; 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (7.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (7.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.64 to 1.38), P = 0.756</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment failure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PCT group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adjusted OR (95% CI), P value</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P for interaction</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>841 (24.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>768 (23.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.80 to 1.01), P = 0.068</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Adherence</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>419 (23.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>381 (21.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.76 to 1.04), P = 0.148</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.752</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low adherence (&lt; 70% or not reporting)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>422 (27.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>387 (25.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.77 to 1.08), P = 0.301</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Allocation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low risk for allocation concealment bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>776 (26.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>699 (24.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.79 to 1.01), P = 0.069</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.486</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High risk for allocation concealment bias (or not reporting)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65 (13.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 (13.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.68 to 1.44), P = 0.939</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Blinding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blinded outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>412 (23.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>367 (21.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.75 to 1.03), P = 0.117</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.574</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No blinded outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429 (26.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>401 (25.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.79 to 1.11), P = 0.438</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/> NA: not applicable<br/> OR: odds ratio<br/> PCT: procalcitonin </p> </div> </div> </section> </section> <section id="CD007498-sec-0081"> <h4 class="title">Secondary outcomes</h4> <section id="CD007498-sec-0082"> <h5 class="title">1. Antibiotic use (initiation of antibiotics, duration of antibiotics, and total exposure to antibiotics (total amount of antibiotic days divided by total number of participants)) </h5> <p>Procalcitonin guidance was associated with a reduction in total antibiotic exposure (mean 8.1 days compared to 5.7 days, regression coefficient ‐2.43 days (95% CI ‐2.71 to ‐2.15), P &lt; 0.001). Also, duration of antibiotic treatment in treated participants was shorter (mean 9.4 days compared to 8.0 days, adjusted coefficient ‐1.83 days (95% CI ‐2.15 to ‐1.5), P &lt; 0.001) (<a href="#CD007498-tbl-0007">Table 6</a>). </p> <div class="table" id="CD007498-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Antibiotic treatment overall and stratified by setting and ARI diagnosis</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parameter</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PCT group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of effect: adjusted OR or difference (95% CI), P value</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P for interaction</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3372</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3336</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2894 (86.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2351 (71.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.27 (0.24 to 0.32), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4 ± 6.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0 ± 6.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.83 (‐2.15 to ‐1.50), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 ± 6.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7 ± 6.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.43 (‐2.71 to ‐2.15), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Setting‐specific outcomes</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary care</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>501</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>316 (63.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (22.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13 (0.09 to 0.18), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3 ± 2.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0 ± 2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.52 (‐1.07 to 0.04), P = 0.068</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.064</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6 ± 4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 ± 3.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.02 (‐3.45 to ‐2.58), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.101</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Emergency department</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1638</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1615</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1354 (83.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1119 (71.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.49 (0.41 to 0.58), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 ± 5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3 ± 5.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.45 (‐2.86 to ‐2.05), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 ± 6.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2 ± 5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.02 (‐3.41 to ‐2.62), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1233</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1214</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1224 (99.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1116 (91.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (0.01 to 0.05), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5 ± 7.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.8 ± 7.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.23 (‐1.82 to ‐0.65), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5 ± 7.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 ± 7.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.44 (‐1.99 to ‐0.88), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Disease‐specific outcomes</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Community‐acquired pneumonia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1468</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1442</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1455 (99.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1340 (92.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08 (0.04 to 0.15), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5 ± 6.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0 ± 5.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.45 (‐2.87 to ‐2.02), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4 ± 6.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5 ± 5.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.94 (‐3.38 to ‐2.50), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.004</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbation of COPD</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>631</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453 (71.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>266 (42.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.23 to 0.36), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.017</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4 ± 5.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 ± 6.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.15 (‐2.00 to ‐0.31), P = 0.007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.003</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 ± 5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1 ± 5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.22 (‐2.83 to ‐1.60), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.506</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute bronchitis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189 (65.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (26.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.18 (0.12 to 0.26), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1 ± 3.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 ± 3.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.35 (‐1.15 to 0.45), P = 0.393</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.359</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.7 ± 4.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 ± 3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.95 (‐3.59 to ‐2.31), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventilator‐associated pneumonia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186 (100.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193 (99.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.1 ± 7.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8 ± 8.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.22 (‐3.80 to ‐0.65), P = 0.006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.253</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.1 ± 7.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8 ± 8.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.45 (‐4.09 to ‐0.82), P = 0.003</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.786</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Note: Duration refers to the total days of antibiotic therapy in participants in whom antibiotics were initiated. Total exposure refers to the total days of antibiotic therapy in all randomised participants. </p> <p>Measures of effect: dichotomous outcomes are reported as adjusted OR (95% CI) and continuous outcomes are adjusted mean differences and confidence intervals </p> <p>ARI: acute respiratory infection<br/> CI: confidence interval<br/> COPD: chronic obstructive pulmonary disease<br/> NA: not applicable<br/> OR: odds ratio<br/> PCT: procalcitonin<br/> SD: standard deviation </p> </div> </div> </section> <section id="CD007498-sec-0083"> <h5 class="title">2. Length of hospital stay for hospitalised participants</h5> <p>However, the effect on antibiotic consumption differed according to clinical setting. In the primary care setting, lower antibiotic exposure was mainly due to lower initial prescription rates (P &lt; 0.001 for interaction between primary care setting and PCT group on antibiotic prescriptions). Similarly, lower antibiotic exposure due to lower prescription rates was found in selected infections such as acute bronchitis (adjusted OR 0.18, 95% CI 0.12 to 0.26; P for interaction &lt; 0.001). Lower antibiotic prescription rates (adjusted OR 0.49, 95% CI 0.41 to 0.58) and shorter duration of antibiotic therapy in participants with initiation of antibiotic (adjusted coefficient ‐2.45 days, 95% CI ‐2.86 to ‐2.05) contributed to the lower overall exposure in the emergency department setting. </p> <p>Length of hospital stay and ICU stay were similar in both groups with no evidence for different effects in subgroups (P for interaction &gt; 0.05). </p> </section> <section id="CD007498-sec-0084"> <h5 class="title">3. Length of ICU stay for critically ill participants</h5> <p>For the ICU setting, the lower exposure was mainly explained by shorter treatment durations (adjusted difference in days ‐1.23, 95% CI ‐1.82 to ‐0.65). Similarly, for CAP, the lower exposure was mainly explained by shorter durations (adjusted difference in days ‐2.45, 95% CI ‐2.87 to ‐2.02). </p> </section> <section id="CD007498-sec-0085"> <h5 class="title">4. Number of days with restricted activities within 14 days after randomisation for primary care participants </h5> <p>For studies conducted in the primary care setting, there was no difference in days with restricted activities of daily living between PCT and control group participants (days, 8.9 ± 4.2 versus 8.9 ± 4.1, regression coefficient 0.07 (95% CI ‐0.44 to 0.59), P = 0.777). </p> </section> <section id="CD007498-sec-0086"> <h5 class="title">5. Antibiotic‐related side effects</h5> <p>There was also a significant reduction in antibiotic‐related side effects (16.3% versus 22.1%, adjusted OR 0.68, 95% CI 0.57 to 0.82, P &lt; 0.001). This outcome was only assessed in some of the primary care and emergency department trials (n = 6), and not in ICU trials. There was no evidence for subgroup effects (P for interaction &gt; 0.05). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007498-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007498-sec-0087"></div> <section id="CD007498-sec-0088"> <h3 class="title" id="CD007498-sec-0088">Summary of main results</h3> <p>This updated systematic review and meta‐analysis included 32 trials, of which 26 trials were used for the main individual participant data analysis. Trials were conducted in 12 countries and included different clinical settings and types of respiratory infections. There was mostly low risk for random sequence generation, allocation concealment, incomplete outcome data, and selective reporting. There was unclear risk in all studies for blinding of personnel, and mostly high risk for blinding of outcome assessment. The results indicate a significant reduction in mortality (high‐quality evidence according to GRADE, <a href="./full#CD007498-tbl-0001">summary of findings Table for the main comparison</a>) and non‐significant result for treatment failure (moderate‐quality evidence according to GRADE, <a href="./full#CD007498-tbl-0001">summary of findings Table for the main comparison</a>) when PCT was used to guide initiation and duration of antibiotic treatment in ARI participants compared to control participants. Additionally, antibiotic consumption and side effects from antibiotics were significantly reduced across different clinical settings and types of ARIs. There was no effect on length of hospital stay and ICU length of stay. Results were similar in subgroup and sensitivity analyses including an aggregate data analysis with all 32 potentially eligible trials. Limitations include incomplete individual participant data, with four research groups not agreeing to the sharing of individual participant data; incomplete follow‐up information in some of the trials where no outcome assessment was done after 30 days of enrolment; differences in definitions of treatment failure among trials; and exclusion of some patient populations such as immunosuppressed people. Still, results from this updated individual participant data meta‐analysis support the use of PCT in the context of antibiotic stewardship in people with ARIs. </p> </section> <section id="CD007498-sec-0089"> <h3 class="title" id="CD007498-sec-0089">Overall completeness and applicability of evidence</h3> <p>The strengths of our review include an explicit study protocol, a comprehensive search to retrieve all relevant trials, access to individual participant‐level data from all but four of the included trials, and standardised outcome definitions across trials, thereby overcoming limitations of meta‐analyses using aggregated data. To minimise the risk of data‐driven associations, we prespecified a limited number of prognostic factors and subgroup variables for our statistical model. We allowed for potential clustering effects by using random‐effects models for included trials. Our results proved robust in sensitivity analyses focusing on high‐quality trials and on participants with complete follow‐up data. </p> <p>The accuracy of PCT for diagnosing bacterial infections has been called into question by previous meta‐analyses of observational studies, which demonstrated mixed results (<a href="./references#CD007498-bbs2-0037" title="JonesAE , FiechtlJF , BrownMD , BallewJJ , KlineJA . Procalcitonin test in the diagnosis of bacteremia: a meta‐analysis. Annals of Emergency Medicine2007;50(1):34‐41. ">Jones 2007</a>; <a href="./references#CD007498-bbs2-0044" title="SimmondsMC , HigginsJP , StewartLA , TierneyJF , ClarkeMJ , ThompsonSG . Meta‐analysis of individual patient data from randomized trials: a review of methods used in practice. Clinical Trials2005;2(3):209‐17. ">Simmonds 2005</a>; <a href="./references#CD007498-bbs2-0047" title="TangBM , EslickGD , CraigJC , McLeanAS . Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta‐analysis. Lancet Infectious Diseases2007;7(3):210‐7. ">Tang 2007</a>; <a href="./references#CD007498-bbs2-0049" title="UzzanB , CohenR , NicolasP , CucheratM , PerretGY . Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta‐analysis. Critical Care Medicine2006;34(7):1996‐2003. ">Uzzan 2006</a>). However, a more recent meta‐analysis using positive culture as the reference method found moderate to high discrimination of systematic inflammatory response syndrome and sepsis (<a href="./references#CD007498-bbs2-0099" title="WackerC , PrknoA , BrunkhorstFM , SchlattmannP . Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta‐analysis. Lancet Infectious Diseases2013;13(5):426‐35. ">Wacker 2013</a>). Since there are no available gold standards for the diagnosis of the clinical conditions included in our analysis, most studies used clinical consensus criteria, which may differ among studies. Rather than relying on these imperfect diagnostic criteria, we were able to assess the value of PCT algorithms by means of RCTs measuring clinically relevant, participant‐level outcomes. </p> <p>Despite these merits, this review has several limitations. We limited our analysis to adults with ARIs who were mostly immunocompetent, and excluded some pathogens (i.e. <i>Legionella</i> or <i>Pseudomonas</i> infections). The results of these trials may therefore not be generalised to people who are immunocompromised, with specific pathogens or infections other than ARIs, or children. Previous RCTs have shown that PCT guidance also reduces antibiotic exposure in a neonatal sepsis population but not in children with fever without a source (<a href="./references#CD007498-bbs2-0080" title="ManzanoS , BaileyB , GirodiasJB , Galetto‐LacourA , CousineauJ , DelvinE . Impact of procalcitonin on the management of children aged 1 to 36 months presenting with fever without source: a randomized controlled trial. American Journal of Emergency Medicine2010;28(6):647‐53. ">Manzano 2010</a>). We found several ongoing RCTs in children evaluating PCT algorithms that should shed further light on the benefits and harms of PCT use for children. The included trials compared the PCT strategy to a control group where antibiotic therapy was guided based on 'usual practice' or based on current guideline recommendations. The magnitude of antibiotic reduction obviously correlates strongly with antibiotic prescription patterns, and in regions of low antibiotic prescription the PCT strategy may have smaller effects. </p> </section> <section id="CD007498-sec-0090"> <h3 class="title" id="CD007498-sec-0090">Quality of the evidence</h3> <p>Characteristics of the individual trials are presented in <a href="#CD007498-tbl-0002">Table 1</a>. Most trials had a follow‐up of one month, with two trials assessing outcome after 14 to 21 days and several trials following participants until hospital discharge (or ICU discharge) only. Procalcitonin algorithms used in the different trials were similar in concept and recommended initiation and/or continuation of antibiotic therapy based on similar PCT cut‐off levels (<a href="#CD007498-tbl-0002">Table 1</a>). However, there were differences: some trials in primary care and the emergency department used only a single PCT measurement on admission to guide initiation of antibiotics (<a href="./references#CD007498-bbs2-0006" title="BurkhardtO , EwigS , HaagenU , GiersdorfS , HartmannO , WegscheiderK , et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. European Respiratory Journal2010;36(3):601‐7. ">Burkhardt 2010</a>; <a href="./references#CD007498-bbs2-0007" title="Christ‐CrainM , Jaccard‐StolzD , BingisserR , GencayM , HuberP , TammM , et al. Effect of procalcitonin‐guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster‐randomised, single‐blinded intervention trial. Lancet2004;1363(9409):600‐7. ">Christ‐Crain 2004</a>), while the other trials (predominantly in hospitalised participants with severe infections) used repeated measurements for guiding the duration of treatment. Adherence to algorithms was variable. In terms of methodological quality, trials had concealed allocation, but in several trials blinded outcome assessment was not done. All trials achieved complete or near‐complete follow‐up for mortality. None of the trials blinded participants or physicians to group allocation. The overall quality of the evidence according to GRADE was moderate to high (<a href="./full#CD007498-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD007498-sec-0091"> <h3 class="title" id="CD007498-sec-0091">Potential biases in the review process</h3> <p>Due to the differences in patient populations included in this analysis, which ranged from primary care to the ICU, we adapted the definition of treatment failure to clinical settings by including setting‐specific components in this composite outcome. This may challenge the clinical interpretation in the overall analysis. </p> </section> <section id="CD007498-sec-0092"> <h3 class="title" id="CD007498-sec-0092">Agreements and disagreements with other studies or reviews</h3> <p>While mortality did not differ significantly in our initial meta‐analysis (adjusted OR 0.94, 95% CI 0.71 to 1.23) (<a href="./references#CD007498-bbs2-0104" title="SchuetzP , MullerB , Christ‐CrainM , StolzD , TammM , BouadmaL , et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD007498.pub2] ">Schuetz 2012</a>), we found a significantly lower mortality rate in PCT‐guided participants in this update. This result was robust in subgroup analyses and in our sensitivity analysis. Also, when considering all trials in the aggregate data analysis, mortality tended to be reduced, although not significantly (OR 0.89, 95% CI 0.78 to 1.01). Importantly, the largest‐yet ICU trial from the Netherlands has reported a significantly lower mortality in PCT‐guided participants (<a href="./references#CD007498-bbs2-0010" title="DeJongE , vanOersJA , BeishuizenA , VosP , VermeijdenWJ , HaasLE , et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open‐label trial. Lancet Infectious Diseases2016;16(7):819‐27. ">De Jong 2016</a>). </p> <p>Two of the included individual trials reported reduced length of stay, particularly within the ICU. Yet, despite a marked reduction in the duration of antibiotic therapy across trials and settings, there was no difference in length of ICU and hospital stay between the two groups in our comprehensive analysis. One might expect that clinically stable patients with discontinued intravenous antibiotics could be safely discharged unless there are extenuating circumstances. Perceived needs by physicians to further monitor these patients in the unit or inability to transfer patients to other inpatient or aftercare locations may partly explain this finding. </p> <p>There is ongoing controversy about the diagnostic performance of PCT and other blood markers to correctly identify patients with a bacterial infection. In fact, several observational studies have questioned the added value of PCT in addition to clinical signs, such as a primary care study authored by van Vugt and colleagues reporting no additional benefit of PCT to a clinical assessment (<a href="./references#CD007498-bbs2-0098" title="vanVugtSF , BroekhuizenBD , LammensC , ZuithoffNP , deJongPA , CoenenS , et al. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ2013;346:f2450. ">van Vugt 2013</a>). Importantly, in the context of respiratory infections, diagnostic studies are limited by the lack of a reference standard, with blood cultures only detecting a minority of cases (e.g. only 10% to 20% of patients with clinically and radiologically confirmed CAP have positive blood cultures) (<a href="./references#CD007498-bbs2-0085" title="MullerF , Christ‐CrainM , BregenzerT , KrauseM , ZimmerliW , MuellerB , et al. Procalcitonin levels predict bacteremia in patients with community‐acquired pneumonia: a prospective cohort trial. Chest2010;138(1):121‐9. ">Muller 2010</a>; <a href="./references#CD007498-bbs2-0099" title="WackerC , PrknoA , BrunkhorstFM , SchlattmannP . Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta‐analysis. Lancet Infectious Diseases2013;13(5):426‐35. ">Wacker 2013</a>). Interventional research, such as the trials included in the current analysis, do not rely on a reference standard but compare resource use (e.g. antibiotics) and clinical outcomes in people with and without use of the diagnostic marker. For the primary care setting, PCT had a very strong effect on antibiotic consumption (reduction of antibiotic exposure by 70%, from 4.6 to 1.6 days) without compromising disease resolution and patient safety. Of note, we were not able to assess the effect of PCT on mortality due to the very low risk situation with only one non‐survivor (control group) among the 1008 included participants. </p> <p>The available evidence from RCTs, as summarised in this report, supports the use of PCT for de‐escalation of antibiotic therapy for people with ARIs. The same may not be true for escalation of antibiotic therapy when PCT levels increase as demonstrated in a recent large sepsis trial (<a href="./references#CD007498-bbs2-0036" title="JensenJU , HeinL , LundgrenB , BestleMH , MohrTT , AndersenMH , et al. Procalcitonin‐guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Critical Care Medicine2011;39(9):2048‐58. ">Jensen 2011</a>), where PCT‐guided escalation of diagnostic procedures and antimicrobial therapy in the ICU did not improve survival and led to organ‐related harm and prolonged ICU stays. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007498-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram.Abbreviations: ARI: acute respiratory infection; IPD: individual participant data; RCT: randomised controlled trial" data-id="CD007498-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> <p>Abbreviations: ARI: acute respiratory infection; IPD: individual participant data; RCT: randomised controlled trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007498-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007498-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007498-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007498-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007498-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, outcome: 1.1 Mortality at 30 days." data-id="CD007498-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, outcome: 1.1 Mortality at 30 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007498-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, outcome: 1.1 Mortality at 30 days." data-id="CD007498-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, outcome: 1.1 Mortality at 30 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007498-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, outcome: 1.2 Treatment failure at 30 days." data-id="CD007498-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, outcome: 1.2 Treatment failure at 30 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007498-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, Outcome 1 Mortality at 30 days." data-id="CD007498-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, Outcome 1 Mortality at 30 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/references#CD007498-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007498-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, Outcome 2 Treatment failure at 30 days." data-id="CD007498-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting, Outcome 2 Treatment failure at 30 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/references#CD007498-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007498-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses, Outcome 1 Mortality at 30 days stratified by adherence." data-id="CD007498-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses, Outcome 1 Mortality at 30 days stratified by adherence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/references#CD007498-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007498-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses, Outcome 2 Treatment failure at 30 days stratified by adherence." data-id="CD007498-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses, Outcome 2 Treatment failure at 30 days stratified by adherence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/references#CD007498-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007498-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses, Outcome 3 Mortality at 30 days stratified by allocation concealment." data-id="CD007498-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses, Outcome 3 Mortality at 30 days stratified by allocation concealment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/references#CD007498-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007498-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses, Outcome 4 Treatment failure at 30 days stratified by allocation concealment." data-id="CD007498-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses, Outcome 4 Treatment failure at 30 days stratified by allocation concealment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/references#CD007498-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007498-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses, Outcome 5 Mortality at 30 days stratified by blinded outcome assessment." data-id="CD007498-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses, Outcome 5 Mortality at 30 days stratified by blinded outcome assessment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/references#CD007498-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007498-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses, Outcome 6 Treatment failure at 30 days stratified by blinded outcome assessment." data-id="CD007498-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses, Outcome 6 Treatment failure at 30 days stratified by blinded outcome assessment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/references#CD007498-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007498-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/urn:x-wiley:14651858:media:CD007498:CD007498-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_t/tCD007498-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses, Outcome 7 Mortality at 30 days stratified by follow up." data-id="CD007498-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses, Outcome 7 Mortality at 30 days stratified by follow up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/references#CD007498-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/media/CDSR/CD007498/image_n/nCD007498-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007498-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Procalcitonin algorithm compared to standard care for guiding antibiotic therapy in acute respiratory tract infections</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Procalcitonin algorithm compared to standard care for guiding antibiotic therapy in acute respiratory tract infections</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with acute respiratory tract infections<br/> <b>Settings:</b> primary care, emergency department, intensive care unit<br/> <b>Intervention:</b> PCT‐guided care<br/> <b>Comparison:</b> standard care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Standard care</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>PCTalgorithm</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: 30 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.83</b><br/> (0.70 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6708<br/> (26 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b> </p> <p>(76 to 95)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment failure</b><br/> Clinical assessment<sup>3</sup><br/> Follow‐up: 30 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.90</b> <br/> (0.80 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6708<br/> (26 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>249 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1000</b> </p> <p>(216 to 245)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic‐related side effects</b> </p> <p>Follow‐up: 30 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Study population</b> </p> <p><b>221 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>163 per 1000</b> </p> <p>(145 to 182)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.68</b> <br/> (0.57 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3034<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic exposure</b><br/> Total days of antibiotic therapy in all randomised participants </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean antibiotic exposure in the control groups was<br/> <b>8.1 days</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean antibiotic exposure in the intervention groups was<br/> 2.43 days<b>lower</b><br/> (2.15 to 2.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6708<br/> (26 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio: <b>PCT:</b> procalcitonin </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No downgrading for serious concerns. Still, there is some concern about unconcealed allocation in several trials in the emergency department and intensive care settings. There is also some concern about low adherence with the PCT algorithm in the intervention group. We consider unblinded outcome assessment as not relevant for the outcome of death.<br/> <sup>2</sup>Downgraded one level for serious inconsistency: trials used differing definition of treatment failure and some rare events were not systematically assessed among trials.<br/> <sup>3</sup>For the primary care setting, treatment failure was defined as death, hospitalisation, acute respiratory infection (ARI)‐specific complications (e.g. empyema for lower ARI, meningitis for upper ARI), recurrent or worsening infection, and participants reporting any symptoms of an ongoing respiratory infection (e.g. fever, cough, dyspnoea) at follow‐up. For the emergency department setting, treatment failure was defined as death, intensive care unit (ICU) admission, rehospitalisation after index hospital discharge, ARI‐associated complications (e.g. empyema or acute respiratory distress syndrome for lower ARI), and recurrent or worsening infection within 30 days of follow‐up. For the ICU setting, treatment failure was defined as death within 30 days of follow‐up.<br/> <sup>4</sup>Downgraded one level for incomplete reporting: only 6 trials reported side effects from antibiotics, and none of these trials were conducted in the ICU setting. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Procalcitonin algorithm compared to standard care for guiding antibiotic therapy in acute respiratory tract infections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007498-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included trials</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting, type of trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical diagnosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of PCTalgorithm and PCTcut‐offs used (µg/L)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N: ARI participants (study total)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary endpoint</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up time</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reasons for exclusion of patients</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0001" title="AnnaneD , MaximeV , FallerJP , MezherC , Clec'hC , MartelP , et al. Procalcitonin levels to guide antibiotic therapy in adults with non‐microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open2013;3(2):pii: e002186. ">Annane 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe sepsis without overt source of infection and negative blood culture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.5 (&lt; 0.25); R for AB: &gt; 0.5 (&gt; 5.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (62)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants on AB on day 5 post randomisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital stay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 non‐ARI patients (4 of them with post randomisation consent withdrawal)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0002" title="BloosF , TripsE , NierhausA , BriegelJ , HeylandDK , JaschinskiU , et al. Effect of sodium selenite administration and procalcitonin‐guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Internal Medicine2016;176(9):1266‐76. ">Bloos 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe sepsis or septic shock</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinuation at day 4, 7, and 10; R against AB: &lt; 1.0 or &gt; 50% drop to previous value </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219 (1180)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28‐day mortality</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 post randomisation exclusions (informed consent not obtainable), 870 not ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0003" title="BouadmaL , LuytCE , TubachF , CraccoC , AlvarezA , SchwebelC , et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet2010;375(9713):463‐74. ">Bouadma 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suspected bacterial infections during ICU stay without prior AB (&gt; 24 h)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.5 (&lt; 0.25); R for AB: &gt; 0.5 (&gt; 1.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>394 (630)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 post randomisation exclusions (8 withdrew consent, 1 randomised twice); 227 non‐ARI patients </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0004" title="BrancheAR , WalshEE , VargasR , HulbertB , FormicaMA , BaranA , et al. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. Journal of Infectious Diseases2015;212(11):1692‐700. ">Branche 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, medical ward, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower ARI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25 (&gt; 0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265 (300)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic exposure and safety</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0005" title="BrielM , SchuetzP , MuellerB , YoungJ , SchildU , NusbaumerC , et al. Procalcitonin‐guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Archives of Internal Medicine2008;168(18):2000‐7. ">Briel 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary care, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Upper and lower ARI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25 (&gt; 0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458 (458)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days with restricted activities</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No exclusions</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0006" title="BurkhardtO , EwigS , HaagenU , GiersdorfS , HartmannO , WegscheiderK , et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. European Respiratory Journal2010;36(3):601‐7. ">Burkhardt 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary care, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Upper and lower ARI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation; R against AB: &lt; 0.25; R for AB: &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550 (571)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days with restricted activities</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 post randomisation exclusions (2 withdrew consent, 1 due to loss of sample, 15 with autoimmune, inflammatory, or systemic disease, 2 with advanced liver disease, 1 with prior use of antibiotics) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0007" title="Christ‐CrainM , Jaccard‐StolzD , BingisserR , GencayM , HuberP , TammM , et al. Effect of procalcitonin‐guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster‐randomised, single‐blinded intervention trial. Lancet2004;1363(9409):600‐7. ">Christ‐Crain 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower ARI with X‐ray confirmation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25 (&gt; 0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219 (243)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0008" title="Christ‐CrainM , StolzD , BingisserR , MullerC , MiedingerD , HuberPR , et al. Procalcitonin guidance of antibiotic therapy in community‐acquired pneumonia: a randomized trial. American Journal of Respiratory and Critical Care Medicine2006;174(1):84‐93. ">Christ‐Crain 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, medical ward, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAP with X‐ray confirmation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25 (&gt; 0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286 (302)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0009" title="CortiC , FallyM , Fabricius‐BjerreA , MortensenK , JensenBN , AndreassenHF , et al. Point‐of‐care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. International Journal of Chronic Obstructructive Pulmonary Disease2016;11:1381‐9. [DOI: 10.2147/COPD.S104051] ">Corti 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Denmark</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AECOPD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB &lt; 0.25 (0.15)/80% decrease; R for AB &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 (120)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No exclusions</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0010" title="DeJongE , vanOersJA , BeishuizenA , VosP , VermeijdenWJ , HaasLE , et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open‐label trial. Lancet Infectious Diseases2016;16(7):819‐27. ">De Jong 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Netherlands</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critically ill patients with presumed infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 0.5 or &gt; 80% drop</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>994 (1575)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 post randomisation exclusions (25 protocol violations, 4 withdrew informed consent), 552 non‐ARI patients </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0011" title="DeliberatoRO , MarraAR , SanchesPR , MartinoMD , FerreiraCE , PasternakJ , et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagnostic Microbiology and Infectious Disease2013;76(3):266‐71. ">Deliberato 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Septic patients with proven bacterial infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 0.5 or &gt; 90% drop</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU discharge or 14 days' post randomisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0012" title="DingJ , ChenZ , FengK . Procalcitonin‐guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. International Journal of Medical Sciences2013;10(7):903‐7. ">Ding 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute exacerbation of pulmonary fibrosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25; R for AB: &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 post randomisation exclusions (7 lost to follow‐up, 3 withdrew informed consent), 68 data not shared </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0013" title="HochreiterM , KohlerT , SchweigerAM , KeckFS , BeinB , vonSpiegelT , et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care2009;13(3):R83. ">Hochreiter 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suspected bacterial infections and &gt; 1 SIRS criteria</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 1 or &gt; 65% drop over 3 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (110)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital stay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0014" title="KristoffersenKB , SogaardOS , WejseC , BlackFT , GreveT , TarpB , et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission ‐ a randomized trial. Clinical Microbiology and Infection2009;15(5):481‐7. ">Kristoffersen 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Denmark</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, medical ward, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower ARI without X‐ray confirmation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25; R for AB: &gt; 0.25 (&gt; 0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210 (223)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital stay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 post randomisation exclusions (3 no PCT testing, 6 not meeting inclusion criteria, 4 withdrew informed consent) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0015" title="LayiosN , LambermontB , CanivetJL , MorimontP , PreiserJC , GarwegC , et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Critical Care Medicine2012;40(8):2304‐9. ">Layios 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Belgium</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suspected infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation; R against AB: &lt; 0.5 (&lt; 0.25); R for AB: &gt; 0.5 (&gt; 1.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 (509)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 no PCT measurements, 10 missing data, 219 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0016" title="LimaSS , NobreV , deCastro RomanelliRM , ClementeWT , daSilva BittencourtHN , MeloAC , et al. Procalcitonin‐guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Annals of Hematology2016;95(7):1169‐76. ">Lima 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, medical ward, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Febrile neutropenia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 0.5 for 2 days or &gt; 90% drop than highest measured concentration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (62)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 post randomisation exclusion (withdrew informed consent), 62 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0017" title="LongW , DengXQ , TangJG , XieJ , ZhangYC , ZhangY , et al. Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community acquired pneumonia. Zhonghua Nei Ke Za Zhi2009;48(3):216‐9. ">Long 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, outpatients, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAP with X‐ray confirmation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25; R for AB: &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (149)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 post randomisation exclusions due to withdrawal of consent</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0018" title="LongW , DengX , ZhangY , LuG , XieJ , TangJ . Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community acquired pneumonia. Respirology2011;76(1):266‐9. ">Long 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, outpatients, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAP with X‐ray confirmation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25; R for AB: &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 (172)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 post randomisation exclusions (6 lost to follow‐up, 7 withdrew consent, 3 with final diagnosis other than CAP) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0019" title="LongW , LiLJ , HuangGZ , ZhangXM , ZhangYC , TangJG , et al. Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12‐month follow‐up. Critical Care2014;18(5):471. ">Long 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe acute exacerbation of asthma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (180)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No exclusions</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0020" title="Maravić‐StojkovićV , Laušević‐VukL , JovićM , RankovićA , BorzanovićM , MarinkovićJ . Procalcitonin‐based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: a randomized controlled trial. Srpski Arhiv Celokupno Lekarstvo2011;139(11‐12):736‐42. ">Maravić‐Stojković 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serbia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU surgical, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infection after open heart surgery</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation; R for AB: &gt; 0.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (205)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use, AB cost</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital stay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0021" title="NajafiA , KhodadadianA , SanatkarM , Shariat MoharariR , EtezadiF , AhmadiA , et al. The comparison of procalcitonin guidance administer antibiotics with empiric antibiotic therapy in critically ill patients admitted in intensive care unit. Acta Medica Iranica2015;53(9):562‐7. ">Najafi 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SIRS without apparent source of infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation; R for AB: &gt; 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (60)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital stay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 patient data not shared</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0022" title="NobreV , HarbarthS , GrafJD , RohnerP , PuginJ . Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. American Journal of Respiratory and Critical Care Medicine2009;177(5):498‐505. ">Nobre 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suspected severe sepsis or septic shock</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 0.5 (&lt; 0.25) or &gt; 80% drop; R for AB: &gt; 0.5 (&gt; 1.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 (79)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0023" title="OgasawaraT , UmezawaH , NaitoY , TakeuchiT , KatoS , YanoT , et al. Procalcitonin‐guided antibiotic therapy in aspiration pneumonia and an assessment of the continuation of oral intake. Respiratory Investigation2014;52(2):107‐13. ">Ogasawara 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medical ward, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aspiration pneumonia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Predefined duration; AB for 3 d: &lt; 0.5; AB for 5 d: 0.5 to 1.0; AB for 7 d: &gt; 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (105)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse and 30‐day mortality</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 post randomisation exclusions (2 withdrew consent, 7 others), 96 data not shared</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0024" title="OliveiraCF , BotoniFA , OliveiraCR , SilvaCB , PereiraHA , SerufoJC , et al. Procalcitonin versus C‐reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Critical Care Medicine2013;41(10):2336‐43. ">Oliveira 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe sepsis or septic shock</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinuation; initial &lt; 1.0: R against AB: 0.1 at day 4; initial &gt; 1.0: R against: &gt; 90% drop </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days or hospital discharge</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 post randomisation exclusions (2 withdrew consent, 1 technical problems), 36 patients with a final diagnosis other than ARI </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0025" title="SchroederS , HochreiterM , KoehlerT , SchweigerAM , BeinB , KeckFS , et al. Procalcitonin (PCT)‐guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Archives of Surgery2009;394(2):221‐6. ">Schroeder 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe sepsis following abdominal surgery</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 1 or &gt; 65% drop over 3 d</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital stay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0026" title="SchuetzP , Christ‐CrainM , ThomannR , FalconnierC , WolbersM , WidmerI , et al. Effect of procalcitonin‐based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA2009;302(10):1059‐66. ">Schuetz 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, medical ward, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower ARI with X‐ray confirmation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25 (&gt; 0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1304 (1381)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 post randomisation exclusions due to withdrawal of consent, 55 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0027" title="ShehabiY , SterbaM , GarrettPM , RachakondaKS , StephensD , HarriganP , et al. ProGUARD Study Investigators, ANZICS Clinical Trials Group. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2014;190(10):1102‐10. ">Shehabi 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suspected sepsis, undifferentiated infections</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 0.25 (&lt; 0.1) or &gt; 90% drop</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 (400)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 post randomisation exclusions (6 withdrew consent), 238 non‐ARI patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0028" title="StolzD , Christ‐CrainM , BingisserR , LeuppiJ , MiedingerD , MullerC , et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin‐guidance with standard therapy. Chest2007;131(1):9‐19. ">Stolz 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, medical ward, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbated COPD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25 (&gt; 0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208 (226)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to 3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 post randomisation exclusions (absence of COPD)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0029" title="StolzD , SmyrniosN , EggimannP , ParggerH , ThakkarN , SiegemundM , et al. Procalcitonin for reduced antibiotic exposure in ventilator‐associated pneumonia: a randomised study. European Respiratory Journal2009;34(6):1364‐75. ">Stolz 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland, USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAP when intubated &gt; 48 h</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration; R against AB: &lt; 0.5 (&lt; 0.25) or &gt; 80% drop; R for AB: &gt; 0.5 (&gt; 1.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 (101)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB‐free days alive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No exclusions</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0030" title="TangJ , LongW , YanL , ZhangY , XieJ , LuG , et al. Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial. BMC Infectious Diseases2013;13:596. [DOI: 10.1186/1471‐2334‐13‐596] ">Tang 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation of asthma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation and duration; R against AB: &lt; 0.25 (&lt; 0.1); R for AB: &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (265)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB use</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 post randomisation exclusions (5 lost to follow‐up, 3 died, 2 withdrew consent), 255 data not shared </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0031" title="VerduriA , LuppiF , D'AmicoR , BalduzziS , ViciniR , LiveraniA , et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS ONE2015;10(3):e0118241. ">Verduri 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED, medical ward, multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AECOPD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation; R against AB:&lt; 0.1; R for AB: &gt; 0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178 (183)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of exacerbations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 post randomisation exclusions (5 lost to follow‐up because they did not meet the inclusion criteria) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0032" title="WangJX , ZhangSM , LiXH , ZhangY , XuZY , CaoB . Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. International Journal of Infectious Diseases2016;48:40‐5. [DOI: 10.1016/j.ijid.2016.04.024] ">Wang 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU, single centre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AECOPD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants had initial PCT &lt; 0.1; AB group treated with AB for at least 3 days, control group no AB in the first 10 days </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191 (194)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment success within 10 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 post randomisation exclusions (3 with pneumonia according to CT scan)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>AB: antibiotic<br/> AECOPD: acute exacerbation of chronic obstructive pulmonary disease<br/> ARI: acute respiratory infection<br/> CAP: community‐acquired pneumonia<br/> COPD: chronic obstructive pulmonary disease<br/> CT: computed tomography<br/> d: days<br/> ED: emergency department<br/> h: hours<br/> ICU: intensive care unit<br/> PCT: procalcitonin<br/> R: recommendation for or against antibiotics<br/> SIRS: systemic inflammatory response syndrome<br/> VAP: ventilator‐associated pneumonia </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007498-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of included participants</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parameter</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control (n = 3372)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PCT group (n = 3336)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Demographics</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age (year), mean (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.2 ± 18.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.7 ± 18.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male gender, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1910 (56.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1898 (56.9%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Clinical setting, no (%)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary care</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>501 (14.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (15.2%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Emergency department</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1638 (48.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1615 (48.4%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intensive care unit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1233 (36.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1214 (36.4%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Primary diagnosis</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total upper ARI, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280 (8.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>292 (8.8%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common cold</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 (4.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149 (4.5%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rhino‐sinusitis, otitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (2.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (2.2%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharyngitis, tonsillitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (1.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 (1.8%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total lower ARI, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3092 (91.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3044 (91.2%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐acquired pneumonia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1468 (43.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1442 (43.2%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐acquired pneumonia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 (7.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243 (7.3%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ventilator‐associated pneumonia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186 (5.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 (5.8%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute bronchitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287 (8.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257 (7.7%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation of COPD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>631 (18.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621 (18.6%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation of asthma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (3.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 (4.3%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other lower ARI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 (3.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144 (4.3%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Procalcitonin upon enrolment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCT&lt; 0.1 ug/L</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>921 (35.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>981 (30.9%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCT 0.1 to 0.25 ug/L</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521 (20.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>608 (19.2%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCT &gt; 0.25 to 0.5 ug/L</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>308 (11.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>383 (12.1%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCT &gt; 0.5 to 2.0 ug/L</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>358 (13.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>520 (16.4%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCT &gt; 2.0 ug/L</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>482 (18.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>679 (21.4%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>ARI: acute respiratory infection<br/> COPD: chronic obstructive pulmonary disease<br/> PCT: procalcitonin<br/> SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of included participants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007498-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Quality assessment of trials</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Allocation concealment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Blinded<br/> outcome assessment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up for mortality</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adherence to PCT algorithm in PCT group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up for mortality</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0001" title="AnnaneD , MaximeV , FallerJP , MezherC , Clec'hC , MartelP , et al. Procalcitonin levels to guide antibiotic therapy in adults with non‐microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open2013;3(2):pii: e002186. ">Annane 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58/58 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0002" title="BloosF , TripsE , NierhausA , BriegelJ , HeylandDK , JaschinskiU , et al. Effect of sodium selenite administration and procalcitonin‐guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Internal Medicine2016;176(9):1266‐76. ">Bloos 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1045/1089 (96%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.6% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days and 90 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0003" title="BouadmaL , LuytCE , TubachF , CraccoC , AlvarezA , SchwebelC , et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet2010;375(9713):463‐74. ">Bouadma 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>393/394 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days and 60 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0004" title="BrancheAR , WalshEE , VargasR , HulbertB , FormicaMA , BaranA , et al. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. Journal of Infectious Diseases2015;212(11):1692‐700. ">Branche 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation using blocks of 4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250/300 (83.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month and 3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0005" title="BrielM , SchuetzP , MuellerB , YoungJ , SchildU , NusbaumerC , et al. Procalcitonin‐guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Archives of Internal Medicine2008;168(18):2000‐7. ">Briel 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>454/458 (99%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0006" title="BurkhardtO , EwigS , HaagenU , GiersdorfS , HartmannO , WegscheiderK , et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. European Respiratory Journal2010;36(3):601‐7. ">Burkhardt 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>546/550 (99%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0007" title="Christ‐CrainM , Jaccard‐StolzD , BingisserR , GencayM , HuberP , TammM , et al. Effect of procalcitonin‐guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster‐randomised, single‐blinded intervention trial. Lancet2004;1363(9409):600‐7. ">Christ‐Crain 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No (alternating weeks)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230/243 (95%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 to 14 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0008" title="Christ‐CrainM , StolzD , BingisserR , MullerC , MiedingerD , HuberPR , et al. Procalcitonin guidance of antibiotic therapy in community‐acquired pneumonia: a randomized trial. American Journal of Respiratory and Critical Care Medicine2006;174(1):84‐93. ">Christ‐Crain 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (sequentially numbered, opaque, sealed envelopes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300/302 (99%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0009" title="CortiC , FallyM , Fabricius‐BjerreA , MortensenK , JensenBN , AndreassenHF , et al. Point‐of‐care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. International Journal of Chronic Obstructructive Pulmonary Disease2016;11:1381‐9. [DOI: 10.2147/COPD.S104051] ">Corti 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (randomisation algorithm was concealed to treating clinicians and participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120/120 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.1% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0010" title="DeJongE , vanOersJA , BeishuizenA , VosP , VermeijdenWJ , HaasLE , et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open‐label trial. Lancet Infectious Diseases2016;16(7):819‐27. ">De Jong 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1546/1546 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days and 1 year</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0011" title="DeliberatoRO , MarraAR , SanchesPR , MartinoMD , FerreiraCE , PasternakJ , et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagnostic Microbiology and Infectious Disease2013;76(3):266‐71. ">Deliberato 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (opaque, sealed envelopes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81/81 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0012" title="DingJ , ChenZ , FengK . Procalcitonin‐guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. International Journal of Medical Sciences2013;10(7):903‐7. ">Ding 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68/78 (87.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0013" title="HochreiterM , KohlerT , SchweigerAM , KeckFS , BeinB , vonSpiegelT , et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care2009;13(3):R83. ">Hochreiter 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No (unconcealed drawing of lots)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43/43 (100% until discharge)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0014" title="KristoffersenKB , SogaardOS , WejseC , BlackFT , GreveT , TarpB , et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission ‐ a randomized trial. Clinical Microbiology and Infection2009;15(5):481‐7. ">Kristoffersen 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210/210 (100% until discharge)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0015" title="LayiosN , LambermontB , CanivetJL , MorimontP , PreiserJC , GarwegC , et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Critical Care Medicine2012;40(8):2304‐9. ">Layios 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>509/509 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intensive care unit LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0016" title="LimaSS , NobreV , deCastro RomanelliRM , ClementeWT , daSilva BittencourtHN , MeloAC , et al. Procalcitonin‐guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Annals of Hematology2016;95(7):1169‐76. ">Lima 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (sequentially numbered, opaque, sealed envelopes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61/62 (98.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.3% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days and 90 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0017" title="LongW , DengXQ , TangJG , XieJ , ZhangYC , ZhangY , et al. Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community acquired pneumonia. Zhonghua Nei Ke Za Zhi2009;48(3):216‐9. ">Long 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No (odd and even patient ID numbers)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127/127 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0018" title="LongW , DengX , ZhangY , LuG , XieJ , TangJ . Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community acquired pneumonia. Respirology2011;76(1):266‐9. ">Long 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No (odd and even patient ID numbers)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156/156 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0019" title="LongW , LiLJ , HuangGZ , ZhangXM , ZhangYC , TangJG , et al. Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12‐month follow‐up. Critical Care2014;18(5):471. ">Long 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169/180 (93.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.6% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS and 1 year</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0020" title="Maravić‐StojkovićV , Laušević‐VukL , JovićM , RankovićA , BorzanovićM , MarinkovićJ . Procalcitonin‐based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: a randomized controlled trial. Srpski Arhiv Celokupno Lekarstvo2011;139(11‐12):736‐42. ">Maravić‐Stojković 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205/205 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days and LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0021" title="NajafiA , KhodadadianA , SanatkarM , Shariat MoharariR , EtezadiF , AhmadiA , et al. The comparison of procalcitonin guidance administer antibiotics with empiric antibiotic therapy in critically ill patients admitted in intensive care unit. Acta Medica Iranica2015;53(9):562‐7. ">Najafi 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/30 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0022" title="NobreV , HarbarthS , GrafJD , RohnerP , PuginJ . Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. American Journal of Respiratory and Critical Care Medicine2009;177(5):498‐505. ">Nobre 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (sequentially numbered, opaque, sealed envelopes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52/52 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days and LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0023" title="OgasawaraT , UmezawaH , NaitoY , TakeuchiT , KatoS , YanoT , et al. Procalcitonin‐guided antibiotic therapy in aspiration pneumonia and an assessment of the continuation of oral intake. Respiratory Investigation2014;52(2):107‐13. ">Ogasawara 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96/96 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0024" title="OliveiraCF , BotoniFA , OliveiraCR , SilvaCB , PereiraHA , SerufoJC , et al. Procalcitonin versus C‐reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Critical Care Medicine2013;41(10):2336‐43. ">Oliveira 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94/94 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.2% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0025" title="SchroederS , HochreiterM , KoehlerT , SchweigerAM , BeinB , KeckFS , et al. Procalcitonin (PCT)‐guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Archives of Surgery2009;394(2):221‐6. ">Schroeder 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No (unconcealed drawing of lots)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/8 (100% until discharge)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0026" title="SchuetzP , Christ‐CrainM , ThomannR , FalconnierC , WolbersM , WidmerI , et al. Effect of procalcitonin‐based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA2009;302(10):1059‐66. ">Schuetz 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1358/1359 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91% adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0027" title="ShehabiY , SterbaM , GarrettPM , RachakondaKS , StephensD , HarriganP , et al. ProGUARD Study Investigators, ANZICS Clinical Trials Group. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2014;190(10):1102‐10. ">Shehabi 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>394/394 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS and 90 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0028" title="StolzD , Christ‐CrainM , BingisserR , LeuppiJ , MiedingerD , MullerC , et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin‐guidance with standard therapy. Chest2007;131(1):9‐19. ">Stolz 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (sequentially numbered, opaque, sealed envelopes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208/208 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0029" title="StolzD , SmyrniosN , EggimannP , ParggerH , ThakkarN , SiegemundM , et al. Procalcitonin for reduced antibiotic exposure in ventilator‐associated pneumonia: a randomised study. European Respiratory Journal2009;34(6):1364‐75. ">Stolz 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (sequentially numbered, opaque, sealed envelopes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101/101 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0030" title="TangJ , LongW , YanL , ZhangY , XieJ , LuG , et al. Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial. BMC Infectious Diseases2013;13:596. [DOI: 10.1186/1471‐2334‐13‐596] ">Tang 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (sequentially numbered, opaque, sealed envelopes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258/265 (97.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0031" title="VerduriA , LuppiF , D'AmicoR , BalduzziS , ViciniR , LiveraniA , et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS ONE2015;10(3):e0118241. ">Verduri 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (central randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178/178 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007498-bbs2-0032" title="WangJX , ZhangSM , LiXH , ZhangY , XuZY , CaoB . Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. International Journal of Infectious Diseases2016;48:40‐5. [DOI: 10.1016/j.ijid.2016.04.024] ">Wang 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (those responsible for allocation concealment were not involved in the measurement of results) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191/191 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.3% adherence (17 participants in the control group received AB)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>LOS: length of stay<br/> PCT: procalcitonin </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Quality assessment of trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007498-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Clinical endpoints overall and stratified by setting and ARI diagnosis</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PCT group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of effect: adjusted OR or difference (95% CI), P value</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P for interaction</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3372</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3336</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>336 (10.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286 (8.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.70 to 0.99), P = 0.037</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>841 (24.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>768 (23.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.80 to 1.01), P = 0.068</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of ICU stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3 ± 16.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7 ± 17.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39 (‐0.81 to 1.58), P = 0.524</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7 ± 20.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.4 ± 18.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.19 (‐0.96 to 0.58), P = 0.626</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic‐related side effects, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>336 (22.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247 (16.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.57 to 0.82), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>According to setting</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary care</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>501</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (0.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164 (32.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159 (31.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.73 to 1.25), P = 0.751</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.715</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days with restricted activities, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9 ± 4.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9 ± 4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (‐0.44 to 0.59), P = 0.777</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic‐related side effects, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 (25.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 (20.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.46 to 0.91), P = 0.012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.596</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Emergency department</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1638</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1615</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (3.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (3.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.63 to 1.33), P = 0.635</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.546</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>292 (17.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259 (16.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87 (0.72 to 1.05), P = 0.141</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.807</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 ± 10.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 ± 7.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.14 (‐0.73 to 0.44), P = 0.631</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.684</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic‐related side effects, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208 (20.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145 (14.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.52 to 0.83), P = 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.596</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1233</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1214</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273 (22.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229 (19.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.69 to 1.02), P = 0.081</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.619</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of ICU stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.8 ± 16.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.3 ± 17.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56 (‐0.82 to 1.93), P = 0.427</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.849</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.3 ± 26.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.8 ± 23.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.33 (‐2.28 to 1.62), P = 0.739</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.641</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>According to diagnosis</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Community‐acquired pneumonia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1468</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1442</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206 (14.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175 (12.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.66 to 1.03), P = 0.083</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.958</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385 (26.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317 (22.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (0.66 to 0.93), P = 0.005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.052</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of ICU stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5 ± 10.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.9 ± 13.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.45 (0.15 to 2.75), P = 0.029</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.119</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3 ± 15.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9 ± 16.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74 (‐0.25 to 1.73), P = 0.143</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.094</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic‐related side effects, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186 (27.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (19.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62 (0.48 to 0.80), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.227</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbation of COPD</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>631</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (3.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (3.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 (0.43 to 1.48), P = 0.472</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.847</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (17.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 (16.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.70 to 1.27), P = 0.704</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.676</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.3 ± 13.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4 ± 7.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.60 (‐1.84 to 0.64), P = 0.342</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.658</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic‐related side effects, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (10.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (10.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.53 to 1.63), P = 0.805</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.198</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute bronchitis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (0.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 (19.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 (20.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 (0.72 to 1.70), P = 0.643</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6 ± 5.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 ± 4.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.21 (‐0.90 to 0.48), P = 0.556</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotic‐related side effects, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (21.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (17.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (0.49 to 1.22), P = 0.263</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.657</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventilator‐associated pneumonia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days mortality, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (15.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (12.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 (0.41 to 1.39), P = 0.366</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.644</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment failure, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (27.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (22.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (0.48 to 1.28), P = 0.332</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.522</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of ICU stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.5 ± 20.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.8 ± 19.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.74 (‐5.64 to 2.17), P = 0.383</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.441</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay, mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.8 ± 27.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.0 ± 23.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.14 (‐7.04 to 2.75), P = 0.391</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.448</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Measures of effect: dichotomous outcomes are reported as adjusted OR (95% CI) and continuous outcomes are adjusted mean differences and confidence intervals </p> <p>ARI: acute respiratory infection<br/> CI: confidence interval<br/> COPD: chronic obstructive pulmonary disease<br/> ICU: intensive care unit<br/> NA: not applicable<br/> OR: odds ratio<br/> PCT: procalcitonin<br/> SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Clinical endpoints overall and stratified by setting and ARI diagnosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007498-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analysis</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Main analysis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PCT group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adjusted OR (95% CI), P value</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P for interaction</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>336 (10.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>286 (8.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.70 to 0.99), P = 0.037</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Adherence</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82 (4.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 (4.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.63 to 1.22), P = 0.434</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.617</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low adherence (&lt; 70% or not reporting)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254 (16.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>211 (14.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.67 to 1.02), P = 0.073</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Allocation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low risk for allocation concealment bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>305 (10.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 (8.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.67 to 0.97), P = 0.021</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.229</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High risk for allocation concealment bias (or not reporting)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (6.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (7.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.66 to 1.91), P = 0.672</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Blinding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blinded outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113 (6.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102 (5.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.64 to 1.13), P = 0.259</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.537</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No blinded outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>223 (13.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184 (11.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.65 to 1.01), P = 0.062</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Follow up for mortality at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>275 (10.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>224 (8.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.67 to 0.99), P = 0.039</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.325</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Follow up for mortality &lt; 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (7.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (7.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.64 to 1.38), P = 0.756</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment failure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PCT group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adjusted OR (95% CI), P value</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P for interaction</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>841 (24.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>768 (23.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.80 to 1.01), P = 0.068</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Adherence</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High adherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>419 (23.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>381 (21.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.76 to 1.04), P = 0.148</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.752</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low adherence (&lt; 70% or not reporting)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>422 (27.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>387 (25.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.77 to 1.08), P = 0.301</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Allocation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low risk for allocation concealment bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>776 (26.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>699 (24.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.79 to 1.01), P = 0.069</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.486</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High risk for allocation concealment bias (or not reporting)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65 (13.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 (13.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.68 to 1.44), P = 0.939</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Blinding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blinded outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>412 (23.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>367 (21.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.75 to 1.03), P = 0.117</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.574</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No blinded outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429 (26.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>401 (25.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.79 to 1.11), P = 0.438</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval<br/> NA: not applicable<br/> OR: odds ratio<br/> PCT: procalcitonin </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007498-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Antibiotic treatment overall and stratified by setting and ARI diagnosis</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parameter</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PCT group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of effect: adjusted OR or difference (95% CI), P value</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P for interaction</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3372</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3336</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2894 (86.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2351 (71.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.27 (0.24 to 0.32), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4 ± 6.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0 ± 6.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.83 (‐2.15 to ‐1.50), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 ± 6.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7 ± 6.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.43 (‐2.71 to ‐2.15), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Setting‐specific outcomes</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary care</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>501</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>316 (63.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 (22.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13 (0.09 to 0.18), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3 ± 2.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0 ± 2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.52 (‐1.07 to 0.04), P = 0.068</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.064</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6 ± 4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 ± 3.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.02 (‐3.45 to ‐2.58), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.101</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Emergency department</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1638</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1615</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1354 (83.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1119 (71.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.49 (0.41 to 0.58), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 ± 5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3 ± 5.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.45 (‐2.86 to ‐2.05), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 ± 6.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2 ± 5.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.02 (‐3.41 to ‐2.62), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intensive care unit</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1233</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1214</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1224 (99.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1116 (91.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (0.01 to 0.05), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5 ± 7.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.8 ± 7.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.23 (‐1.82 to ‐0.65), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5 ± 7.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 ± 7.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.44 (‐1.99 to ‐0.88), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Disease‐specific outcomes</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Community‐acquired pneumonia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1468</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1442</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1455 (99.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1340 (92.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08 (0.04 to 0.15), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5 ± 6.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0 ± 5.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.45 (‐2.87 to ‐2.02), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4 ± 6.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5 ± 5.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.94 (‐3.38 to ‐2.50), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.004</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbation of COPD</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>631</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453 (71.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>266 (42.8%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.23 to 0.36), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.017</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4 ± 5.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 ± 6.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.15 (‐2.00 to ‐0.31), P = 0.007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.003</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 ± 5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1 ± 5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.22 (‐2.83 to ‐1.60), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.506</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute bronchitis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189 (65.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (26.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.18 (0.12 to 0.26), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1 ± 3.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 ± 3.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.35 (‐1.15 to 0.45), P = 0.393</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.359</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.7 ± 4.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 ± 3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.95 (‐3.59 to ‐2.31), P &lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ventilator‐associated pneumonia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initiation of antibiotics, n (%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186 (100.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193 (99.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.1 ± 7.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8 ± 8.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.22 (‐3.80 to ‐0.65), P = 0.006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.253</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total exposure of antibiotics (days), mean (±SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.1 ± 7.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8 ± 8.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.45 (‐4.09 to ‐0.82), P = 0.003</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.786</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Note: Duration refers to the total days of antibiotic therapy in participants in whom antibiotics were initiated. Total exposure refers to the total days of antibiotic therapy in all randomised participants. </p> <p>Measures of effect: dichotomous outcomes are reported as adjusted OR (95% CI) and continuous outcomes are adjusted mean differences and confidence intervals </p> <p>ARI: acute respiratory infection<br/> CI: confidence interval<br/> COPD: chronic obstructive pulmonary disease<br/> NA: not applicable<br/> OR: odds ratio<br/> PCT: procalcitonin<br/> SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Antibiotic treatment overall and stratified by setting and ARI diagnosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/full#CD007498-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007498-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.78, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Primary care trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Emergency department trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.70, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Intensive care unit trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.77, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Treatment failure at 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Primary care trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.72, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Emergency department trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.69, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Intensive care unit trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.81, 1.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/references#CD007498-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007498-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at 30 days stratified by adherence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.78, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Adherence to procalcitonin algorithm &gt; 70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.81, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Adherence to procalcitonin algorithm &lt; 70% or not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.73, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Treatment failure at 30 days stratified by adherence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Adherence to procalcitonin algorithm &gt; 70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Adherence to procalcitonin algorithm &lt; 70% or not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.81, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality at 30 days stratified by allocation concealment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.78, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Trials with concealed allocation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.76, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Trials without concealed allocation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2078</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.70, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Treatment failure at 30 days stratified by allocation concealment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Trials with concealed allocation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.82, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Trials without concealed allocation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2078</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.64, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mortality at 30 days stratified by blinded outcome assessment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.78, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Trials with blinded outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.84, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Trials without blinded outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.70, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Treatment failure at 30 days stratified by blinded outcome assessment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Trials with blinded outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.79, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Trials without blinded outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.77, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mortality at 30 days stratified by follow up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.78, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Trials with 1 month follow up for mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.74, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Trials with different follow up for mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.78, 1.30]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007498.pub3/references#CD007498-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007498.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007498-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007498-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD007498-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD007498-note-0002">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD007498-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007498-note-0016">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007498\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007498\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007498\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007498\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007498\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007498.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007498.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007498.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007498.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007498.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714399938"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007498.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714399942"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007498.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6dbf9b6d9377',t:'MTc0MDcxNDQwMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 